WARNINGS
Zidovudine, one of the three active ingredients in Lamivudine, Nevirapine, and Zidovudine Tablets, has been associated with hematologic toxicity including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus 1 (HIV-1) disease [see WARNINGS]. Prolonged use of zidovudine has been associated with symptomatic myopathy (see WARNINGS). Lactic acidosis and hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including lamivudine, zidovudine, and other antiretrovirals. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur (see WARNINGS).

Acute exacerbations of Hepatitis B have been reported in patients who are co-infected with Hepatitis B Virus (HBV) and HIV-1 and have discontinued lamivudine, which is one component of Lamivudine, Nevirapine, and Zidovudine Tablets. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue Lamivudine, Nevirapine, and Zidovudine Tablets and are co-infected with HIV-1 and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted (see WARNINGS).

Severe, life-threatening, and in some cases fatal hepatotoxicity, particularly in the first 18 weeks, has been reported in patients treated with nevirapine, one of the three active ingredients in Lamivudine, Nevirapine, and Zidovudine Tablets. In some cases, patients presented with non-specific prodromal signs or symptoms of hepatitis and progressed to hepatic failure. These events are often associated with rash. Female gender and higher CD4+ cell counts at initiation of therapy place patients at increased risk; women with CD4+ cell counts >250 cells/mm3, including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. However, hepatotoxicity associated with nevirapine use can occur in both genders, all CD4+ cell counts and at any time during treatment. Patients with signs or symptoms of hepatitis, or with increased transaminases combined with rash or other systemic symptoms, must discontinue Lamivudine, Nevirapine, and Zidovudine Tablets seek medical evaluation immediately (see Warnings).

Severe, life-threatening skin reactions, including fatal cases, have occurred in patients treated with
nevirapine, one of the three active ingredients in Lamivudine, Nevirapine, and Zidovudine Tablets. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction. Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue Lamivudine, Nevirapine, Zidovudine Tablets and seek medical evaluation immediately. Transaminase levels should be checked immediately for all patients who develop a rash in the first 18 weeks of treatment. The 14-day lead-in period with nevirapine daily dosing has been observed to decrease the incidence of rash and must be followed [see Warnings and Precautions].

Patients must be monitored intensively during the first 18 weeks of therapy with nevirapine containing drug products to detect potentially life-threatening hepatotoxicity or skin reactions. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of these events. Do not restart Lamivudine, Nevirapine, and Zidovudine Tablets following severe hepatic, skin or hypersensitivity reactions. In some cases, hepatic injury has progressed despite discontinuation of treatment (see WARNINGS and PRECAUTIONS).

DESCRIPTION

Lamivudine/Nevirapine/Zidovudine Tablets for Oral Suspension:
Lamivudine, Nevirapine and Zidovudine Tablets for Oral Suspension are for oral administration. Each scored tablet contains 30 mg of lamivudine USP, 50 mg of nevirapine USP and 60 mg of zidovudine USP. The inactive ingredients are acesulfame potassium, aspartame, colloidal silicon dioxide, ferric oxide yellow, lactose monohydrate, magnesium stearate, microcrystalline cellulose, orange flavor, povidone, and sodium starch glycolate.

Lamivudine and zidovudine are synthetic nucleoside analogues and nevirapine is a non-nucleoside reverse transcriptase inhibitor with activity against HIV.

Lamivudine:
The chemical name of lamivudine is (-)-1-[(2R, 5S)-2-(Hydroxymethyl)-1, 3-oxathiolan-5-yl] cytosine. Lamivudine is the (-) enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (-)2', 3'353 dideoxy, 3'-thiacytidine. It has a molecular formula of C₈H₁₁N₃O₃S and a molecular weight of 229.3. It has the following structural formula:
Lamivudine is a white to off-white crystalline solid with a solubility of approximately 70 mg/mL in water at 20°C.

**Nevirapine:**
The chemical name of nevirapine is 6H-Dipyrido-[3,2-b:2′3′-c][1,4]diazepin-6-one,11-Cyclopropyl-5,11-dihydro-4-methyl. Nevirapine is a white to off-white crystalline powder with the molecular weight of 266.30 and the molecular formula C15H14N4O. Nevirapine has the following structural formula:

![Nevirapine structural formula](image)

**Zidovudine:**
The chemical name of zidovudine is 3′azido-3′-deoxythymidine; it has the following structural formula:

![Zidovudine structural formula](image)

Zidovudine is a white to beige, odorless, crystalline solid with a molecular weight of 267.24 and a solubility of 20.1 mg/mL in water at 25°C. The molecular formula is C10H13N5O4.

**MICROBIOLOGY**

**Lamivudine:**
Mechanism of Action: Intracellularly, lamivudine is phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is the inhibition
of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue into viral DNA. 3 TC-TP is a weak inhibitor of mammalian DNA polymerases α, β, and γ.

Antiviral Activity: The antiviral activity of lamivudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood lymphocytes) using standard susceptibility assays. EC_{50} values (50% effective concentrations) were in the range of 0.003 to 15 µM (1 µM = 0.23 mcg/mL). HIV-1 from therapy-naive subjects with no amino acid substitutions associated with resistance gave median EC_{50} values of 0.429 µM (range: 0.200 to 2.007 µM) from Virco (n = 92 baseline samples from COL40263) and 2.35 µM (1.37 to 3.68 µM) from Monogram Biosciences (n = 135 baseline samples from ESS30009). The EC_{50} values of lamivudine against different HIV-1 clades (A-G) ranged from 0.001 to 0.120 µM, and against HIV-2 isolates from 0.003 to 0.120 µM in peripheral blood mononuclear cells. Ribavirin (50 µM) decreased the anti-HIV-1 activity of lamivudine by 3.5 fold in MT-4 cells. In HIV-1-infected MT-4 cells, lamivudine in combination with zidovudine at various ratios exhibited synergistic antiretroviral activity. Please see the full prescribing information for lamivudine-HBV for information regarding the inhibitory activity of lamivudine against HBV.

Resistance: Lamivudine-resistant variants of HIV-1 have been selected in cell culture. Genotypic analysis showed that the resistance was due to a specific amino acid substitution in the HIV-1 reverse transcriptase at codon 184 changing the methionine to either isoleucine or valine (M184V/I).

HIV-1 strains resistant to both lamivudine and zidovudine have been isolated from patients. Susceptibility of clinical isolates to lamivudine and zidovudine was monitored in controlled clinical trials. In patients receiving lamivudine monotherapy or combination therapy with lamivudine plus zidovudine, HIV-1 isolates from most patients became phenotypically and genotypically resistant to lamivudine within 12 weeks. In some patients harboring zidovudine-resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12 weeks of treatment with lamivudine and zidovudine. Combination therapy with lamivudine plus zidovudine delayed the emergence of mutations conferring resistance to zidovudine.

Lamivudine-resistant HBV isolates develop substitutions (rtM204V/I) in the YMDD motif of the catalytic domain of the viral reverse transcriptase. rtM204V/I substitutions are frequently accompanied by other substitutions (rtV173L, rtL180M) which enhance the level of lamivudine resistance or act as compensatory mutations improving replication efficiency. Other substitutions detected in lamivudine-resistant HBV isolates include: rtL80I and rtA 181 T. Similar HBV mutants have been reported in HIV-1-infected patients who received lamivudine-containing antiretroviral regimens in the presence of concurrent infection with hepatitis B virus (see Warnings and Precautions).
Cross-Resistance: Lamivudine-resistant HIV-1 mutants were cross-resistant to didanosine (ddI) and zalcitabine (ddC). In some patients treated with zidovudine plus didanosine or zalcitabine, isolates resistant to multiple reverse transcriptase inhibitors, including lamivudine, have emerged.

Genotypic and Phenotypic Analysis of On-Therapy HIV-1 Isolates From Patients With Virologic Failure: Study EPV20001: Fifty-three of 554 (10%) patients enrolled in EPV20001 were identified as virological failures (plasma HIV-1 RNA level ≥400 copies/mL) by Week 48. Twenty-eight patients were randomized to the lamivudine once-daily treatment group and 25 to the lamivudine twice-daily treatment group. The median baseline plasma HIV-1 RNA levels of patients in the lamivudine once-daily group and lamivudine twice-daily group were 4.9 log_{10} copies/mL and 4.6 log_{10} copies/mL, respectively.

Genotypic analysis of on-therapy isolates from 22 patients identified as virologic failures in the lamivudine once-daily group showed that isolates from 0/22 patients contained treatment-emergent amino acid substitutions associated with zidovudine resistance (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E), isolates from 10/22 patients contained treatment-emergent amino acid substitutions associated with efavirenz resistance (L100I, K103N, V108I, or Y181C), and isolates from 8/22 patients contained a treatment-emergent lamivudine resistance-associated substitution (M184V).

Genotypic analysis of on-therapy isolates from patients (n=22) in the lamivudine twice-daily treatment group showed that isolates from 1/22 patients contained treatment-emergent zidovudine resistance substitutions, isolates from 7/22 contained treatment-emergent efavirenz resistance substitutions, and isolates from 5/22 contained treatment-emergent lamivudine resistance substitutions.

Phenotypic analysis of baseline-matched on-therapy HIV-1 isolates from patients (n = 13) receiving lamivudine once daily showed that isolates from 12/13 patients were susceptible to zidovudine; isolates from 8/13 patients exhibited a 25- to 295-fold decrease in susceptibility to efavirenz, and isolates from 7/13 patients showed an 85- to 299-fold decrease in susceptibility to lamivudine.

Phenotypic analysis of baseline-matched on-therapy HIV-1 isolates from patients (n= 13) receiving lamivudine twice daily showed that isolates from all 13 patients were susceptible to zidovudine; isolates from 3/13 patients exhibited 21-to 342-fold decrease in susceptibility to efavirenz, and isolates from 4/13 patients exhibited a 29- to 159-fold decrease in susceptibility to lamivudine.

Study EPV40001: Fifty patients received zidovudine 300 mg twice daily plus abacavir 300 mg twice daily plus lamivudine 300 mg once daily and 50 patients received zidovudine 300 mg plus abacavir 300
mg plus lamivudine 150 mg all twice daily. The median baseline plasma HIV-1 RNA levels for patients in the 2 groups were 4.79 log_{10} copies/mL and 4.83 log_{10} copies/mL, respectively. Fourteen of 50 patients in the lamivudine once-daily treatment group and 9 of 50 patients in the lamivudine twice-daily group were identified as virologic failures. Genotypic analysis of on-therapy HIV-1 isolates from patients (n = 9) in the lamivudine once-daily treatment group showed that isolates from 6 patients had an abacavir and/or lamivudine resistance-associated substitution M184V alone. On-therapy isolates from patients (n = 6) receiving lamivudine twice daily showed that isolates from 2 patients had M184V alone, and isolates from 2 patients harbored the M184V substitution in combination with zidovudine resistance-associated amino acid substitutions.

Phenotypic analysis of on-therapy isolates from patients (n = 6) receiving lamivudine once daily showed that HIV-1 isolates from 4 patients exhibited a 32- to 53-fold decrease in susceptibility to lamivudine. HIV-1 isolates from these 6 patients; were susceptible to zidovudine. Phenotypic analysis of on-therapy isolates from patients (n = 4) receiving lamivudine twice daily showed that HIV-1 isolates from 1 patient exhibited a 45-fold decrease in susceptibility to lamivudine and a 4.5-fold decrease in susceptibility to zidovudine.

**Nevirapine:**

**Mechanism of Action**

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases α, β, γ, or δ) are not inhibited by nevirapine.

**Antiviral Activity**

The antiviral activity of nevirapine has been measured in a variety of cell lines including peripheral blood mononuclear cells, monocyte derived macrophages, and lymphoblastoid cell lines. In an assay using human embryonic kidney 293 cells, the median EC50 value (50% inhibitory concentration) of nevirapine was 90 nM against a panel of 2923 isolates of HIV-1 that were primarily (93%) clade B clinical isolates from the United States. The 99th percentile EC50 value was 470 nM in this study. The median EC50 value was 63 nM (range 14-302 nM, n=29) against clinical isolates of HIV-1 clades A, B, C, D, F, G, and H, and circulating recombinant forms CRF01_AE, CRF02_AG and CRF12_BF. Nevirapine had no antiviral activity in cell culture against group O HIV-1 isolates (n=3) or HIV-2 isolates (n=3) replicating in cord blood mononuclear cells. Nevirapine in combination with efavirenz exhibited strong antagonistic
anti-HIV-1 activity in cell culture and was additive to antagonistic with the protease inhibitor ritonavir or the fusion inhibitor enfuvirtide. Nevirapine exhibited additive to synergistic anti-HIV-1 activity in combination with the protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, saquinavir and tipranavir, and the NRTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir and zidovudine. The anti-HIV-1 activity of nevirapine was antagonized by the anti-HBV drug adefovir and by the anti-HCV drug ribavirin in cell culture.

Resistance

HIV-1 isolates with reduced susceptibility (100-250-fold) to nevirapine emerge in cell culture. Genotypic analysis showed mutations in the HIV-1 RT gene encoding Y181C and/or V106A substitutions depending upon the virus strain and cell line employed. Time to emergence of nevirapine resistance in cell culture was not altered when selection included nevirapine in combination with several other NNRTIs.

Phenotypic and genotypic changes in HIV-1 isolates from treatment-naïve patients receiving either nevirapine (n=24) or nevirapine and ZDV (n=14) were monitored in Phase 1 and 2 trials over 1 to ≥12 weeks. After 1 week of nevirapine monotherapy, isolates from 3/3 patients had decreased susceptibility to nevirapine in cell culture. One or more of the RT mutations resulting in amino acid substitutions K103N, V106A, V108I, Y181C, Y188C and G190A were detected in HIV-1 isolates from some patients as early as 2 weeks after therapy initiation. By week eight of nevirapine monotherapy, 100% of the patients tested (n=24) had HIV-1 isolates with a >100-fold decrease in susceptibility to nevirapine in cell culture compared to baseline, and had one or more of the nevirapine-associated RT resistance substitutions. Nineteen of these patients (80%) had isolates with Y181C substitutions regardless of dose.

Genotypic analysis of isolates from antiretroviral naïve patients experiencing virologic failure (n=71) receiving nevirapine once daily (n=25) or twice daily (n=46) in combination with lamivudine and stavudine (study 2NN) for 48 weeks showed that isolates from 8/25 and 23/46 patients, respectively, contained one or more of the following NNRTI resistance-associated substitutions: Y181C, K101E, G190A/S, K103N, V106A/M, V108I, Y188C/L, A98G, F227L and M230L.

Cross-resistance

Rapid emergence of HIV-1 strains which are cross-resistant to NNRTIs has been observed in cell culture. Nevirapine-resistant HIV-1 isolates were cross-resistant to the NNRTIs delavirdine and efavirenz. However, nevirapine-resistant isolates were susceptible to the NRTIs ddI and ZDV. Similarly, ZDV-resistant isolates were susceptible to nevirapine in cell culture.
**Zidovudine:**

**Mechanism of Action:** Zidovudine is a synthetic nucleoside analogue. Intracellularly, zidovudine is phosphorylated to its active 5′-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). The principal mode of action of ZDV-TP is inhibition of reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. ZDV-TP is a weak inhibitor of the cellular DNA polymerases α and γ and has been reported to be incorporated into the DNA of cells in culture.

**Antiviral Activity:** The antiviral activity of zidovudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood lymphocytes). The EC50 and EC90 values for zidovudine were 0.01 to 0.49 µM (1 µM = 0.27 mcg/mL) and 0.1 to 9 µM, respectively. HIV-1 from therapy-naive subjects with no mutations associated with resistance gave median EC50 values of 0.011 µM (range: 0.005 to 0.110 µM) from Virco (n = 92 baseline samples from COL40263) and 0.0017 µM (0.006 to 0.0340 µM) from Monogram Biosciences (n = 135 baseline samples from ESS30009). The EC50 values of zidovudine against different HIV-1 clades (A-G) ranged from 0.00018 to 0.02 µM, and against HIV-2 isolates from 0.00049 to 0.004 µM. In cell culture drug combination studies, zidovudine demonstrates synergistic activity with the nucleoside reverse transcriptase inhibitors abacavir, didanosine, and lamivudine; the non-nucleoside reverse transcriptase inhibitors delavirdine and nevirapine; and the protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir; and additive activity with interferon alfa. Ribavirin has been found to inhibit the phosphorylation of zidovudine in cell culture.

**Resistance:** Genotypic analyses of the isolates selected in cell culture and recovered from zidovudine-treated patients showed mutations in the HIV-1 RT gene resulting in 6 amino acid substitutions (M41L, D67N, K70R, L210W, T215Y or F, and K219Q) that confer zidovudine resistance. In general, higher levels of resistance were associated with a greater number of amino acid substitutions. In some patients harboring zidovudine-resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12 weeks of treatment with lamivudine and zidovudine. Combination therapy with lamivudine plus zidovudine delayed the emergence of substitutions conferring resistance to zidovudine.

**Cross-Resistance:** In a study of 167 HIV-1-infected patients, isolates (n = 2) with multi-drug resistance to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine were recovered from patients treated for ≥1 year with zidovudine plus didanosine or zidovudine plus zalcitabine. The pattern of resistance-associated amino acid substitutions with such combination therapies was different (A62V, V75I, F77L, F116Y, Q151M) from the pattern with zidovudine monotherapy, with the Q151M substitution being most commonly associated with multi-drug resistance. The substitution at codon 151 in combination with substitutions at 62, 75, 77, and 116 results in a virus with reduced susceptibility to didanosine,
lamivudine, stavudine, zalcitabine, and zidovudine. Thymidine analogue mutations (TAMs) are selected by zidovudine and confer cross-resistance to abacavir, didanosine, stavudine, tenofovir, and zalcitabine.

ANIMAL PHARMACOLOGY

Nevirapine: Animal studies have shown that nevirapine is widely distributed to nearly all tissues and readily crosses the blood-brain barrier.

CLINICAL PHARMACOLOGY

Mechanism of Action
Lamivudine, Nevirapine and Zidovudine are antiviral agents (see Clinical Pharmacology).

Pharmacokinetics
The rate and extent of absorption of lamivudine, zidovudine, and nevirapine tablets for oral suspension (two tablets) was similar to that from Epivir® Oral Solution (10 mg/mL lamivudine; 60 mg dose), Viramune® Oral Suspension (50 mg/5mL nevirapine; 100 mg dose), and Retrovir® Syrup (50 mg/5mL zidovudine; 120 mg dose) administered under fasted or fed conditions.

Lamivudine:
Pharmacokinetics in Adults: The pharmacokinetic properties of lamivudine have been studied in asymptomatic, HIV-1-infected-adult patients after administration of single intravenous administration (IV) doses ranging from 0.25 to 8 mg/kg, as well as single and multiple (twice-daily regimen) oral doses ranging from 0.25 to 10 mg/kg.

The pharmacokinetic properties of lamivudine have also been studied as single and multiple oral doses ranging from 5 mg to 600 mg/day administered to HBV-infected patients. The steady-state pharmacokinetic properties of the lamivudine 300-mg tablet once daily for 7 days compared with the lamivudine 150-mg tablet twice daily for 7 days were assessed in a crossover study in 60 healthy volunteers. Lamivudine 300 mg once daily resulted in lamivudine exposures that were similar to lamivudine 150 mg twice daily with respect to plasma AUC\textsubscript{24,ss}, however, C\textsubscript{max,ss} was 66% higher and the trough value was 53% lower compared with the 150-mg twice-daily regimen. Intracellular lamivudine triphosphate exposures in peripheral blood mononuclear cells were also similar with respect to AUC\textsubscript{24,ss} and C\textsubscript{max,ss}, however, trough values were lower compared with the 150-mg twice-daily regimen. Inter-subject variability was greater for intracellular lamivudine triphosphate concentrations versus lamivudine
plasma trough concentrations. The clinical significance of observed differences for both plasma lamivudine concentrations and intracellular lamivudine triphosphate concentrations is not known.

Absorption and Bioavailability: Lamivudine was rapidly absorbed after oral administration in HIV-1-infected patients. Absolute bioavailability in 12 adult patients was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution. After oral 393 administration of 2 mg/kg twice a day to 9 adults with HIV-1; the peak serum lamivudine concentration (C<sub>max</sub>) was 1.5 ± 0.5 mcg/mL (mean ± SD). The area under the plasma concentration versus time curve (AUC) and C<sub>max</sub> increased in proportion to oral dose over the range from 0.25 to 10 mg/kg.

The accumulation ratio of lamivudine in HIV-1-positive asymptomatic adults with normal renal function was 1.50 following 15 days of oral administration of 2 mg/kg twice daily. Effects of Food on Oral Absorption: An investigational 25-mg dosage form of lamivudine was administered orally to 12 asymptomatic, HIV-1-infected patients on 2 occasions, once in the fasted state and once with food (1,099 kcal; 75 grams fat, 34 grams protein, 72 grams carbohydrate). Absorption of lamivudine was slower in the fed state (T<sub>max</sub>: 3.2 ± 1.3 hours) compared with the fasted state (T<sub>max</sub>: 0.9 ± 0.3 hours); C<sub>max</sub> in the fed state was 40% ± 23% (mean ± SD) lower than in the fasted state. There was no significant difference in systemic exposure (AUC<sub>∞</sub>) in the fed and fasted states; therefore, lamivudine tablets and Oral Solution may be administered with or without food.

Distribution: The apparent volume of distribution after iv administration of lamivudine to 20 patients was 1.3 ± 0.4 L/kg, suggesting that lamivudine distributes into extravascular spaces. Volume of distribution was independent of dose and did not correlate with body weight.

Binding of lamivudine to human plasma proteins is low (<36%). In vitro studies showed that over the concentration range of 0.1 to 100 mcg/mL, the amount of lamivudine associated with erythrocytes ranged from 53% to 57% and was independent of concentration.

Metabolism: Metabolism of lamivudine is a minor route of elimination. In man, the only known metabolite of lamivudine is the trans-sulfoxide metabolite. Within 12 hours after a single oral dose of lamivudine in 6 HIV-1-infected adults, 5.2% ± 1.4% (mean ± SD) of the dose was excreted as the trans-sulfoxide metabolite in the urine. Serum concentrations of this metabolite have not been determined.

Elimination: The majority of lamivudine is eliminated unchanged in urine by active organic cationic secretion. In 9 healthy subjects given a single 300-mg oral dose of lamivudine, renal clearance was 199.7± 56.9 mL/min (mean ± SD). In 20 HIV-l-infected patients given a single IV dose, renal clearance
was 280.4 ± 75.2 mL/min (mean ± SD), representing 71 % ± 16% (mean ± SD) of total clearance of lamivudine.

In most single-dose studies in HIV-1-infected patients, HBV-infected patients, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t1/2) ranged from 5 to 7 hours. In HIV-1-infected patients, total clearance was 398.5 ± 69.1 mL/min (mean ± SD). Oral clearance and elimination half-life were independent of dose and body weight over an oral dosing range from 0.25 to 10 mg/kg.

Special Populations: Renal Impairment: The pharmacokinetic properties of lamivudine have been determined in a small group of HIV-1-infected adults with impaired renal function (Table 1).

Table 1. Pharmacokinetic Parameters (Mean ± SD) After a Single 300-mg Oral Dose of Lamivudine in 3 Groups of Adults With Varying Degrees of Renal Function

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Creatinine Clearance Criterion (Number of Subjects)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&gt;60 mL/min (n=6)</td>
</tr>
<tr>
<td>Creatinine clearance (mL/min)</td>
<td>111 ± 14</td>
</tr>
<tr>
<td>Cmax (mcg/mL)</td>
<td>2.6 ± 0.5</td>
</tr>
<tr>
<td>AUC∞ (mcg.hr/mL)</td>
<td>11.0 ± 1.7</td>
</tr>
<tr>
<td>C1/F (mL/min)</td>
<td>464 ± 76</td>
</tr>
</tbody>
</table>

Exposure (AUC ∞), Cmax, and half-life increased with diminishing renal function (as expressed by creatinine clearance). Apparent total oral clearance (C1/F) of lamivudine decreased as creatinine clearance decreased. Tₘₐₓ was not significantly affected by renal function. Based on these observations, it is recommended that the dosage of lamivudine be modified in patients with renal impairment [see Dosage and Administration].

Based on a study in otherwise healthy subjects with impaired renal function, hemodialysis increased lamivudine clearance from a mean of 64 to 88 mL/min; however, the length of time of hemodialysis (4 hours) was insufficient to significantly alter mean lamivudine exposure after a single-dose administration. Continuous ambulatory peritoneal dialysis and automated peritoneal dialysis have negligible effects on lamivudine clearance. Therefore, it is recommended, following correction of dose for creatinine clearance, than no additional dose modification be made after routine hemodialysis or peritoneal dialysis.

It is not known whether lamivudine can be removed by continuous (24-hour) hemodialysis.

The effects of renal impairment on lamivudine pharmacokinetics in pediatric patients are not known.
Hepatic Impairment: The pharmacokinetic properties of lamivudine have been determined in adults with impaired hepatic function. Pharmacokinetic parameters were not altered by diminishing hepatic function; therefore, no dose adjustment for lamivudine is required for patients with impaired hepatic function. Safety and efficacy of lamivudine have not been established in the presence of decompensated liver disease.

Pediatric Patients: In Study NUCA2002, pharmacokinetic properties of lamivudine were assessed in a subset of 57 HIV-1-infected pediatric patients (age range: 4.8 months to 16 years, weight range: 5 to 66 kg) after oral and IV administration of 1, 2, 4, 8, 12, and 20 mg/kg/day. In the 9 infants and children (range: 5 months to 12 years of age) receiving oral solution 4 mg/kg twice daily (the usual recommended pediatric dose), absolute bioavailability was 66% ± 26% (mean ± SD), which was less than the 86% ± 16% (mean ± SD) observed in adults. The mechanism for the diminished absolute bioavailability of lamivudine in infants and children is unknown.

Systemic clearance decreased with increasing age in pediatric patients, as shown in Figure 1.

![Figure 1. Systemic Clearance (L/h/kg) of Lamivudine in Relation to Age](image)

After oral administration of lamivudine 4 mg/kg twice daily to 11 pediatric patients ranging from 4 months to 14 years of age, C\text{max} was 1.1 ± 0.6 mcg/mL and half-life was 2.0 ± 0.6 hours. (In adults with similar blood sampling, the half-life was 3.7 ± 1 hours.) Total exposure to lamivudine, as reflected by mean AUC values, was comparable between pediatric patients receiving an 8-mg/kg/day dose and adults receiving a 4-mg/kg/day dose.

Distribution of lamivudine into cerebrospinal fluid (CSF) was assessed in 38 pediatric patients after multiple oral dosing with lamivudine. CSF samples were collected between 2 and 4 hours postdose. At the dose of 8 mg/kg/day, CSF lamivudine concentrations in 8 patients ranged from 5.6% to 30.9% (mean ± SD of 14.2% ± 7.9%) of the concentration in a simultaneous serum sample, with CSF lamivudine concentrations ranging from 0.04 to 0.3 mcg/mL.

Limited, uncontrolled pharmacokinetic and safety data are available from administration of lamivudine (and zidovudine) to 36 infants up to 1 week of age in 2 studies in South Africa. In these studies,
lamivudine clearance was substantially reduced in 1-week-old neonates relative to pediatric patients (>3 months of age) studied previously. There is insufficient information to establish the time course of changes in clearance between the immediate neonatal period and the age-ranges >3 months old (see Adverse Reactions).

Geriatric Patients: The pharmacokinetics of lamivudine after administration of lamivudine to patients over 65 years of age have not been studied (see Use in Specific Populations).

Gender: There are no significant gender differences in lamivudine pharmacokinetics.

Race: There are no significant racial differences in lamivudine pharmacokinetics.

Drug Interactions: Interferon Alfa: There was no significant pharmacokinetic interaction between lamivudine and interferon alfa in a study of 19 healthy male subjects (see Warnings and Precautions).

Ribavirin: In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions].

Trimethoprim/Sulfamethoxazole: Lamivudine and TMP/SMX were co administered to 14 HIV-1-positive patients in a single-center, open-label, randomized, crossover study. Each patient received treatment with a single 300-mg dose of lamivudine and TMP 160 mg/SMX 800 mg once a day for 5 days with concomitant administration of lamivudine 300 mg with the fifth dose in a crossover design. Coadministration of TMP/SMX with lamivudine resulted in an increase of 43% ± 23% (mean ± SD) in lamivudine AUC∞, a decrease of 29% ± 13% in lamivudine oral clearance, and a decrease of 30% ± 36% in lamivudine renal clearance. The pharmacokinetic properties of TMP and SMX were not altered by coadministration with lamivudine [see Drug Interactions].

Zidovudine: No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed in 12 asymptomatic HIV-1-infected adult patients given a single dose of zidovudine (200 mg) in combination with multiple doses of lamivudine (300 mg q 12 hr) [see Drug Interactions].
**Nevirapine:**

**Adults**

**Absorption and Bioavailability**

Nevirapine is readily absorbed (>90%) after oral administration in healthy volunteers and in adults with HIV-1 infection. Absolute bioavailability in 12 healthy adults following single-dose administration was 93 ± 9% (mean ± SD) for a 50 mg tablet and 91 ± 8% for an oral solution. Peak plasma nevirapine concentrations of 2 ± 0.4 µg/mL (7.5 µM) were attained by 4 hours following a single 200 mg dose. Following multiple doses, nevirapine peak concentrations appear to increase linearly in the dose range of 200 to 400 mg/day. Steady state trough nevirapine concentrations of 4.5 ± 1.9 µg/mL (17 ± 7 µM), (n = 242) were attained at 400 mg/day. Nevirapine tablets and suspension have been shown to be comparably bioavailable and interchangeable at doses up to 200 mg. When nevirapine (200 mg) was administered to 24 healthy adults (12 female, 12 male), with either a high fat breakfast (857 kcal, 50 g fat, 53% of calories from fat) or antacid (Maalox® 30 mL), the extent of nevirapine absorption (AUC) was comparable to that observed under fasting conditions. In a separate study in HIV-1 infected patients (n=6), nevirapine steady-state systemic exposure (AUCt) was not significantly altered by didanosine, which is formulated with an alkaline buffering agent. Nevirapine may be administered with or without food, antacid or didanosine.

**Distribution**

Nevirapine is highly lipophilic and is essentially nonionized at physiologic pH. Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is widely distributed in humans. Nevirapine readily crosses the placenta and is also found in breast milk [see Use In Specific Populations]. Nevirapine is about 60% bound to plasma proteins in the plasma concentration range of 1-10 µg/mL. Nevirapine concentrations in human cerebrospinal fluid (n=6) were 45% (± 5%) of the concentrations in plasma; this ratio is approximately equal to the fraction not bound to plasma protein.

**Metabolism/Elimination**

*In vivo* studies in humans and *in vitro* studies with human liver microsomes have shown that nevirapine is extensively biotransformed via cytochrome P450 (oxidative) metabolism to several hydroxylated metabolites. *In vitro* studies with human liver microsomes suggest that oxidative metabolism of nevirapine is mediated primarily by cytochrome P450 (CYP) isozymes from the CYP3A and CYP2B6 families, although other isozymes may have a secondary role. In a mass balance/excretion study in eight healthy male volunteers dosed to steady state with nevirapine 200 mg given twice daily followed by a single 50 mg dose of 14C-nevirapine, approximately 91.4 ± 10.5% of the radiolabeled dose was
recovered, with urine (81.3 ± 11.1%) representing the primary route of excretion compared to feces (10.1 ± 1.5%). Greater than 80% of the radioactivity in urine was made up of glucuronide conjugates of hydroxylated metabolites. Thus cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of nevirapine biotransformation and elimination in humans. Only a small fraction (<5%) of the radioactivity in urine (representing <3% of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound.

Nevirapine is an inducer of hepatic cytochrome P450 (CYP) metabolic enzymes 3A and 2B6. Nevirapine induces CYP3A and CYP2B6 by approximately 20-25%, as indicated by erythromycin breath test results and urine metabolites. Autoinduction of CYP3A and CYP2B6 mediated metabolism leads to an approximately 1.5 to 2 fold increase in the apparent oral clearance of nevirapine as treatment continues from a single dose to two-to-four weeks of dosing with 200-400 mg/day. Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma, from approximately 45 hours (single dose) to approximately 25-30 hours following multiple dosing with 200-400 mg/day.

Special Populations
Renal Impairment HIV seronegative adults with mild (CrCL 50-79 mL/min; n=7), moderate (CrCL 30-49 mL/min; n=6), or severe (CrCL <30 mL/min; n=4) renal impairment received a single 200 mg dose of nevirapine in a pharmacokinetic study. These subjects did not require dialysis. The study included six additional subjects with renal failure requiring dialysis.

In subjects with renal impairment (mild, moderate or severe), there were no significant changes in the pharmacokinetics of nevirapine. However, subjects requiring dialysis exhibited a 44% reduction in nevirapine AUC over a one-week exposure period. There was also evidence of accumulation of nevirapine hydroxy-metabolites in plasma in subjects requiring dialysis. An additional 200 mg dose following each dialysis treatment is indicated [see Dosage and Administration and Use in Specific Populations].

Hepatic Impairment In a steady state study comparing 46 patients with mild (n=17; expansion of some portal areas; Ishak Score 1-2), moderate (n=20; expansion of most portal areas with occasional portal-to-portal and portal-to-central bridging; Ishak Score 3-4), or severe (n=9; marked bridging with occasional cirrhosis without decompensation indicating Child-Pugh A; Ishak Score 5-6) fibrosis as a measure of hepatic impairment, the multiple dose pharmacokinetic disposition of nevirapine and its five oxidative metabolites were not altered. However, approximately 15% of these patients with hepatic fibrosis had
nevirapine trough concentrations above 9,000 μg/mL (2-fold the usual mean trough). Therefore, patients with hepatic impairment should be monitored carefully for evidence of drug induced toxicity [see Warnings and Precautions]. The patients studied were receiving antiretroviral therapy containing Nevirapine 200 mg twice-daily for at least 6 weeks prior to pharmacokinetic sampling, with a median duration of therapy of 3.4 years.

In a pharmacokinetic study where HIV-negative cirrhotic patients with mild (Child-Pugh A; n=6) or moderate (Child-Pugh B; n=4) hepatic impairment received a single 200 mg dose of nevirapine, a significant increase in the AUC of nevirapine was observed in one patient with Child-Pugh B and ascites suggesting that patients with worsening hepatic function and ascites may be at risk of accumulating nevirapine in the systemic circulation. Because nevirapine induces its own metabolism with multiple dosing, this single dose study may not reflect the impact of hepatic impairment on multiple dose pharmacokinetics.

Do not administer nevirapine to patients with moderate or severe (Child Pugh Class B or C, respectively) hepatic impairment [see Contraindications, Warnings and Precautions, and Use in Specific Populations].

Gender
In the multinational 2NN study, a population pharmacokinetic substudy of 1077 patients was performed that included 391 females. Female patients showed a 13.8% lower clearance of nevirapine than did men. Since neither body weight nor Body Mass Index (BMI) had an influence on the clearance of nevirapine, the effect of gender cannot solely be explained by body size.

Race
An evaluation of nevirapine plasma concentrations (pooled data from several clinical trials) from HIV-1-infected patients (27 Black, 24 Hispanic, 189 Caucasian) revealed no marked difference in nevirapine steady-state trough concentrations (median Cminss = 4.7 μg/mL Black, 3.8 μg/mL Hispanic, 4.3 μg/mL Caucasian) with long-term nevirapine treatment at 400 mg/day. However, the pharmacokinetics of nevirapine have not been evaluated specifically for the effects of ethnicity.

Geriatric Patients
Nevirapine pharmacokinetics in HIV-1-infected adults do not appear to change with age (range 18–68 years); however, nevirapine has not been extensively evaluated in patients beyond the age of 55 years [see Use in Specific Populations].
Pediatric Patients

Pharmacokinetic data for nevirapine have been derived from two sources: a 48 week pediatric trial in South Africa (BI Trial 1100.1368) involving 123 HIV-1 positive, antiretroviral naïve patients aged 3 months to 16 years; and a consolidated analysis of five Pediatric AIDS Clinical Trials Group (PACTG) protocols comprising 495 patients aged 14 days to 19 years.

BI Trial 1100.1368 studied the safety, efficacy, and pharmacokinetics of a weight-based and a body surface area (BSA)-based dosing regimen of nevirapine. In the weight-based regimen, pediatric patients up to 8 years of age received a dose of 4 mg/kg once daily for two weeks followed by 7 mg/kg twice daily thereafter. Patients 8 years and older were dosed 4 mg/kg once daily for two weeks followed by 4 mg/kg twice daily thereafter. In the BSA regimen all pediatric patients received 150 mg/m² once daily for two weeks followed by 150 mg/m² twice daily thereafter [see Use in Specific Populations and Adverse Reactions]. Dosing of nevirapine at 150 mg/m² BID (after a two-week lead in of 150 mg/m² QD) produced geometric mean or mean trough nevirapine concentrations between 4-6 µg/mL (as targeted from adult data). In addition, the observed trough nevirapine concentrations were comparable between the two dosing regimens studied (BSA and weight-based methods).

The consolidated analysis of Pediatric AIDS Clinical Trials Group (PACTG) protocols 245, 356, 366, 377, and 403 allowed for the evaluation of pediatric patients less than 3 months of age (n=17). The plasma nevirapine concentrations observed were within the range observed in adults and the remainder of the pediatric population, but were more variable between patients, particularly in the second month of age. For dose recommendations for pediatric patients see Dosage and Administration.

Drug Interactions [see Drug Interactions] Nevirapine induces hepatic cytochrome P450 metabolic isoenzymes 3A and 2B6. Co-administration of nevirapine and drugs primarily metabolized by CYP3A or CYP2B6 may result in decreased plasma concentrations of these drugs and attenuate their therapeutic effects.

While primarily an inducer of cytochrome P450 3A and 2B6 enzymes, nevirapine may also inhibit this system. Among human hepatic cytochrome P450s, nevirapine was capable in vitro of inhibiting the 10-hydroxylation of (R)-warfarin (CYP3A). The estimated Ki for the inhibition of CYP3A was 270 µM, a concentration that is unlikely to be achieved in patients as the therapeutic range is <25 µM. Therefore, nevirapine may have minimal inhibitory effect on other substrates of CYP3A.

Nevirapine does not appear to affect the plasma concentrations of drugs that are substrates of other CYP450 enzyme systems, such as 1A2, 2D6, 2A6, 2E1, 2C9 or 2C19.
Table 2 (see below) contains the results of drug interaction studies performed with nevirapine and other drugs likely to be co-administered. The effects of nevirapine on the AUC, Cmax, and Cmin of co-administered drugs are summarized. To measure the full potential pharmacokinetic interaction effect following induction, patients on the concomitant drug at steady state were administered 28 days of nevirapine (200 mg QD for 14 days followed by 200 mg BID for 14 days) followed by a steady state reassessment of the concomitant drug.

Table 2. Drug Interactions: Changes in Pharmacokinetic Parameters for Co-administered Drug in the Presence of nevirapine (All interaction studies were conducted in HIV-1 positive patients)

<table>
<thead>
<tr>
<th>Co-administered Drug</th>
<th>Dose of Co-administered Drug</th>
<th>Dose Regimen of NEVIRAPINE</th>
<th>n</th>
<th>% Change of Co-administered Drug Pharmacokinetic Parameters (90% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiretrovirals</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir/Ritonavir</td>
<td>300/100 mg QD day 4–13, then 400/100 mg QD, day 14–23</td>
<td>200 mg BID day 1-23. Subjects were treated with nevirapine prior to study entry.</td>
<td>23</td>
<td>Atazanavir 300/100 mg ↓42 (↓52 to ↓29) Atazanavir 300/100 mg ↓28 (↓40 to ↓14) Atazanavir 400/100 mg ↓19 (↓35 to ↑2) Atazanavir 400/100 mg ↑2 (↑15 to ↑24) Atazanavir 400/100 mg ↓72 (↓80 to ↓60)</td>
</tr>
<tr>
<td>Darunavir/Ritonavir</td>
<td>400/100 mg BID</td>
<td>200 mg BID</td>
<td>8</td>
<td>↑24 (↑3 to ↑57) ↑40 (↑14 to ↑73) ↑2 (↑21 to ↑32)</td>
</tr>
<tr>
<td>Didanosine</td>
<td>100-150 mg BID</td>
<td>200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td>18</td>
<td>⇔ ⇔ §</td>
</tr>
<tr>
<td>Efavirenza</td>
<td>600 mg QD</td>
<td>200 mg QD x 14 days; 400 mg QD x 14 days</td>
<td>17</td>
<td>↓28 (↓34 to ↓14) ↓12 (↓23 to ↑1) ↓32 (↓35 to ↓19)</td>
</tr>
<tr>
<td>Fosamprenavir</td>
<td>1400 mg BID</td>
<td>200 mg BID. Subjects were treated with nevirapine prior to study entry</td>
<td>17</td>
<td>↓33 (↓45 to ↓20) ↓25 (↓37 to ↓10) ↓35 (↓50 to ↓15)</td>
</tr>
<tr>
<td>Fosamprenavir/ Ritonavir</td>
<td>700/100 mg BID</td>
<td>200 mg BID. Subjects were treated with nevirapine prior to study entry</td>
<td>17</td>
<td>↓11 (↓23 to ↑3) ⇔ ↓19 (↓32 to ↓4)</td>
</tr>
<tr>
<td>Indinavir a</td>
<td>800 mg q8H</td>
<td>200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td>19</td>
<td>↓31 (↓39 to ↓22) ↓15 (↓24 to ↓14) ↓44 (↓53 to ↓33)</td>
</tr>
<tr>
<td>Drug</td>
<td>Dose</td>
<td>Route</td>
<td>Notes</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>------</td>
<td>-------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>Lopinavir</td>
<td>300/75 mg/m2 (lopinavir/ritonavir)</td>
<td>7 mg/kg or 4 mg/kg QD x 2 weeks; BID x 1 week</td>
<td>12, 15</td>
<td>↓22 (↓44 to ↑19)</td>
</tr>
<tr>
<td>Lopinavir</td>
<td>400/100 mg BID (lopinavir/ritonavir)</td>
<td>200 mg QD x 14 days; 200 mg BID &gt; 1 year</td>
<td>22, 19</td>
<td>↓27 (↓47 to ↓2)</td>
</tr>
<tr>
<td>Maraviroc</td>
<td>300 mg SD</td>
<td>200 mg QD</td>
<td>8</td>
<td>↑1 (↓35 to ↑55)</td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>750 mg TID</td>
<td>200 mg QD x 14 days; 200 mg QD x 14 days</td>
<td>23</td>
<td>⇔</td>
</tr>
<tr>
<td>Maraviroc</td>
<td>300 mg SD</td>
<td>200 mg QD</td>
<td>8</td>
<td>↑1 (↓35 to ↑55)</td>
</tr>
<tr>
<td>Ritonavir</td>
<td>600 mg BID</td>
<td>200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td>18</td>
<td>⇔</td>
</tr>
<tr>
<td>Stavudine</td>
<td>30-40 mg BID</td>
<td>200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td>22</td>
<td>⇔</td>
</tr>
<tr>
<td>Zalcitabine</td>
<td>0.125-0.25 mg TID</td>
<td>200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td>6</td>
<td>⇔</td>
</tr>
<tr>
<td>Zidovudine</td>
<td>100-200 mg TID</td>
<td>200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td>11</td>
<td>↓28 (↓40 to ↓14)</td>
</tr>
<tr>
<td>Other Medications</td>
<td></td>
<td></td>
<td></td>
<td>AUC</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>500 mg BID</td>
<td>200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td>15</td>
<td>↓31 (↓38 to ↓24)</td>
</tr>
<tr>
<td>Metabolite 14-OH-clarithromycin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinyl estradiol</td>
<td>0.035 mg (as Ortho-Novum® 1/35)</td>
<td>200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td>10</td>
<td>↓20 (↓33 to ↓3)</td>
</tr>
<tr>
<td>Norethindrone</td>
<td>1 mg (as Ortho-Novum® 1/35)</td>
<td></td>
<td></td>
<td>↓19 (↓30 to ↓7)</td>
</tr>
<tr>
<td>Depomedroxy-progesterone acetate</td>
<td>150 mg every 3 months</td>
<td>200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td>32</td>
<td>⇔</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>200 mg QD</td>
<td>200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td>19</td>
<td>⇔</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>400 mg QD</td>
<td>200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td>21</td>
<td>↓72 (↓80 to ↓60)</td>
</tr>
</tbody>
</table>
Methadone\textsuperscript{a}  

| Individual Patient Dosing | 200 mg QD x 14 days; 200 mg BID ≥ 7 days | 9 | In a controlled pharmacokinetic study with 9 patients receiving chronic methadone to whom steady state nevirapine therapy was added, the clearance of methadone was increased by 3-fold resulting in symptoms of withdrawal, requiring dose adjustments in 10 mg segments, in 7 of the 9 patients. Methadone did not have any effect on nevirapine clearance. |

Rifabutin\textsuperscript{a}  

| 150 or 300 mg QD | 200 mg QD x 14 days; 200 mg BID x 14 days | 19 | \(\uparrow\) (\(\downarrow\) to \(\uparrow\)) | \(\uparrow\) (\(\downarrow\) to \(\uparrow\)) | \(\Leftrightarrow\) |

Metabolite 25-O-desacetylrifabutin  

|  | 200 mg QD x 14 days; 200 mg BID x 14 days |  | \(\uparrow\) (\(\downarrow\) to \(\uparrow\)) | \(\uparrow\) (\(\downarrow\) to \(\uparrow\)) | \(\Leftrightarrow\) |

Rifampin\textsuperscript{a}  

| 600 mg QD | 200 mg QD x 14 days; 200 mg BID x 14 days | 14 | \(\uparrow\) (\(\downarrow\) to \(\uparrow\)) | \(\Leftrightarrow\) | \(\Leftrightarrow\) |

\(\$\) = C\textsubscript{min} below detectable level of the assay  
\(\uparrow\) = Increase, \(\downarrow\) = Decrease, \(\Leftrightarrow\) = No Effect  
\(\textsuperscript{a}\text{For information regarding clinical recommendations see Drug Interactions (6).}\)  
\(\textsuperscript{b}\text{Pediatric subjects ranging in age from 6 months to 12 years}\)  
\(\textsuperscript{c}\text{Parallel group design; n for NEVIRAPINE +lopinavir/ritonavir, n for lopinavir/ritonavir alone}\)

Because of the design of the drug interaction trials (addition of 28 days of nevirapine therapy to existing HIV therapy) the effect of the concomitant drug on plasma nevirapine steady state concentrations was estimated by comparison to historical controls.

Administration of rifampin had a clinically significant effect on nevirapine pharmacokinetics, decreasing AUC and C\textsubscript{max} by greater than 50%. Administration of fluconazole resulted in an approximate 100% increase in nevirapine exposure, based on a comparison to historic data [see Drug Interactions]. The effect of other drugs listed in Table 2 on nevirapine pharmacokinetics was not significant. No significant interaction was observed when tipranavir was co-administered with low dose ritonavir and nevirapine.

**Zidovudine:**

Absorption and Bioavailability: In adults, following oral administration, zidovudine is rapidly absorbed and extensively distributed, with peak serum concentrations occurring within 0.5 to 1.5 hours. The AUC was equivalent when zidovudine was administered as Zidovudine Tablets or Syrup compared with zidovudine Capsules. The pharmacokinetic properties of zidovudine in fasting adult patients are summarized in Table 3.
Table 3. Zidovudine Pharmacokinetic Parameters in Fasting Adult Patients

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean ± SD (except where noted)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral bioavailability (%)</td>
<td>64 ± 10 (n = 5)</td>
</tr>
<tr>
<td>Apparent volume of distribution (L/kg)</td>
<td>1.6 ± 0.6 (n = 8)</td>
</tr>
<tr>
<td>Plasma protein binding (%)</td>
<td>&lt;38</td>
</tr>
<tr>
<td>CSF:plasma ratio&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.6 [0.04 to 2.62] (n = 39)</td>
</tr>
<tr>
<td>Systemic clearance (L/hr/kg)</td>
<td>1.6 ± 0.6 (n = 6)</td>
</tr>
<tr>
<td>Renal clearance (L/hr/kg)</td>
<td>0.34 ± 0.05 (n = 9)</td>
</tr>
<tr>
<td>Elimination half-life (hr)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.5 to 3 (n = 19)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Median [range].

<sup>b</sup> Approximate range.

Distribution: The apparent volume of distribution of zidovudine, following oral administration, is 1.6 ± 0.6 L/kg; and binding to plasma protein is low, <38% (Table 3).

Metabolism and Elimination: Zidovudine is primarily eliminated by hepatic metabolism. The major metabolite of zidovudine is GZDV. GZDV AUC is about 3-fold greater than the zidovudine AUC. Urinary recovery of zidovudine and GZDV accounts for 14% and 74%, respectively, of the dose following oral administration. A second metabolite, 3′-amino-3′ deoxythymidine (AMT), has been identified in the plasma following single-dose intravenous (IV) administration of zidovudine. The AMT AUC was one fifth of the zidovudine AUC. Pharmacokinetics of zidovudine were dose independent at oral dosing regimens ranging from 2 mg/kg every 8 hours to 10 mg/kg every 4 hours. Effect of Food on Absorption: zidovudine may be administered with or without food. The zidovudine AUC was similar when a single dose of zidovudine was administered with food. Special Populations: Renal Impairment: Zidovudine clearance was decreased resulting in increased zidovudine and GZDV half-life and AUC in patients with impaired renal function (n = 14) following a single 200-mg oral dose (Table 4). Plasma concentrations of AMT were not determined. A dose adjustment should not be necessary for patients with creatinine clearance (CrCl) ≥ 15 mL/min.

Table 4. Zidovudine Pharmacokinetic Parameters in Patients With Severe Renal Impairment<sup>a</sup>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control Subjects (Normal Renal Function) (n = 6)</th>
<th>Patients With Renal Impairment (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CrCl (mL/min)</td>
<td>120 ± 8</td>
<td>18 ± 2</td>
</tr>
<tr>
<td>Zidovudine AUC (ng•hr/mL)</td>
<td>1,400 ± 200</td>
<td>3,100 ± 300</td>
</tr>
<tr>
<td>Zidovudine half-life (hr)</td>
<td>1.0 ± 0.2</td>
<td>1.4 ± 0.1</td>
</tr>
</tbody>
</table>

<sup>a</sup> Data are expressed as mean ± standard deviation.

Hemodialysis and Peritoneal Dialysis: The pharmacokinetics and tolerance of zidovudine were evaluated in a multiple-dose study in patients undergoing hemodialysis (n = 5) or peritoneal dialysis (n = 6) receiving escalating doses up to 200 mg 5 times daily for 8 weeks. Daily doses of 500 mg or less were well tolerated despite significantly elevated GZDV plasma concentrations. Apparent zidovudine oral clearance was approximately 50% of that reported in patients with normal renal function. Hemodialysis
and peritoneal dialysis appeared to have a negligible effect on the removal of zidovudine, whereas GZDV elimination was enhanced. A dosage adjustment is recommended for patients undergoing hemodialysis or peritoneal dialysis [see Dosage and Administration].

**Hepatic Impairment:** Data describing the effect of hepatic impairment on the pharmacokinetics of zidovudine are limited. However, because zidovudine is eliminated primarily by hepatic metabolism, it is expected that zidovudine clearance would be decreased and plasma concentrations would be increased following administration of the recommended adult doses to patients with hepatic impairment [see Dosage and Administration].

Pediatric Patients: Zidovudine pharmacokinetics have been evaluated in HIV-1-infected pediatric patients (Table 5).

**Patients 3 Months to 12 Years of Age:** Overall, zidovudine pharmacokinetics in pediatric patients greater than 3 months of age are similar to those in adult patients. Proportional increases in plasma zidovudine concentrations were observed following administration of oral solution from 90 to 240 mg/m² every 6 hours. Oral bioavailability, terminal half-life, and oral clearance were comparable to adult values. As in adult patients, the major route of elimination was by metabolism to GZDV. After intravenous dosing, about 29% of the dose was excreted in the urine unchanged, and about 45% of the dose was excreted as GZDV [see Dosage and Administration].

**Patients <3 Months of Age:** Zidovudine pharmacokinetics have been evaluated in pediatric patients from birth to 3 months of life. Zidovudine elimination was determined immediately following birth in 8 neonates who were exposed to zidovudine in utero. The half-life was 13.0 ± 5.8 hours. In neonates ≤14 days old, bioavailability was greater, total body clearance was slower, and half-life was longer than in pediatric patients >14 days old. For dose recommendations for neonates [see Dosage and Administration].

<table>
<thead>
<tr>
<th>Table 5. Zidovudine Pharmacokinetic Parameters in Pediatric Patientsa</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parameter</strong></td>
</tr>
<tr>
<td>Oral bioavailability (%)</td>
</tr>
<tr>
<td>CSF:plasma ratio</td>
</tr>
<tr>
<td>CL (L/hr/kg)</td>
</tr>
<tr>
<td>Elimination half-life (hr)</td>
</tr>
</tbody>
</table>

a Data presented as mean ± standard deviation except where noted.  
b Median [range].
Pregnancy: Zidovudine pharmacokinetics have been studied in a Phase I study of 8 women during the last trimester of pregnancy. Zidovudine pharmacokinetics were similar to those of nonpregnant adults. Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery [see Use in Specific Populations].

Although data are limited, methadone maintenance therapy in 5 pregnant women did not appear to alter zidovudine pharmacokinetics.

*Nursing Mothers:* The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1. After administration of a single dose of 200 mg zidovudine to 13 HIV-1-infected women, the mean concentration of zidovudine was similar in human milk and serum [see Use In Specific Population].

*Geriatric Patients:* Zidovudine pharmacokinetics have not been studied in patients over 65 years of age.

*Gender:* A pharmacokinetic study in healthy male (n = 12) and female (n = 12) subjects showed no differences in zidovudine AUC when a single dose of zidovudine was administered as the 300-mg zidovudine Tablet.

**Drug Interactions:** [See Drug Interactions].

<table>
<thead>
<tr>
<th>Coadministered Drug and Dose</th>
<th>Zidovudine Dose</th>
<th>n</th>
<th>Zidovudine Concentrations</th>
<th>Concentration of Coadministered Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atovaquone 750 mg q 12 hr with food</td>
<td>200 mg q 8 hr</td>
<td>14</td>
<td>↑AUC 31%</td>
<td>Range 23% to 78%b</td>
</tr>
<tr>
<td>Clarithromycin 500 mg twice daily</td>
<td>100 mg q 4 hr x 7 days</td>
<td>4</td>
<td>↓AUC 12%</td>
<td>Range ↓34% to ↑14%</td>
</tr>
<tr>
<td>Fluconazole 400 mg daily</td>
<td>200 mg q 8 hr</td>
<td>12</td>
<td>↑AUC 74%</td>
<td>95% CI: 54% to 98%</td>
</tr>
<tr>
<td>Lamivudine 300 mg q 12 hr</td>
<td>single 200 mg</td>
<td>12</td>
<td>↑AUC 13%</td>
<td>90% CI: 2% to 27%</td>
</tr>
<tr>
<td>Methadone 30 to 90 mg daily</td>
<td>200 mg q 4 hr</td>
<td>9</td>
<td>↑AUC 43%</td>
<td>Range 16% to 64%b</td>
</tr>
<tr>
<td>Nelfinavir 750 mg q 8 hr x 7 to 10 days</td>
<td>single 200 mg</td>
<td>11</td>
<td>↑AUC 35%</td>
<td>Range 28% to 41%</td>
</tr>
<tr>
<td>Probencid 500 mg q 6 hr x 2 days</td>
<td>2 mg/kg q 8 hr x 3 days</td>
<td>3</td>
<td>↑AUC 106%</td>
<td>Range 100% to 170%b</td>
</tr>
<tr>
<td>Rifampin 600 mg daily x 14 days</td>
<td>200 mg q 8 hr x 14 days</td>
<td>8</td>
<td>↓AUC 47%</td>
<td>90% CI: 41% to 53%</td>
</tr>
<tr>
<td>Ritonavir 300 mg q 6 hr x 4 days</td>
<td>200 mg q 8 hr x 4 days</td>
<td>9</td>
<td>↓AUC 25%</td>
<td>95% CI: 15% to 34%</td>
</tr>
</tbody>
</table>

Note: ROUTINE DOSE MODIFICATION OF ZIDOVIDINE IS NOT WARRANTED WITH COADMINISTRATION OF THE FOLLOWING DRUGS.
Phenytoin: Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented. However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300-mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed. Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.

Ribavirin: In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions].

INDICATIONS AND USAGE

Lamivudine, Nevirapine, and Zidovudine Tablets are indicated alone or in combination with other antiretrovirals for the treatment of HIV-1 infection.

Additional important information regarding the use of nevirapine (one component of Lamivudine, Nevirapine, and Zidovudine Tablets) for the treatment of HIV-1 infection:

• Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled studies, nevirapine should not be initiated in adult females with CD4+ cell counts greater than 250 cells/mm³ or in adult males with CD4+ cell counts greater than 400 cells/mm³ unless the benefit outweighs the risk. [See Warnings].

• A 14-day lead-in period with nevirapine once daily dosing has been demonstrated to reduce the frequency of rash (see WARNINGS and DOSAGE AND ADMINISTRATION).

• If rash persists beyond the 14 day lead-in period, do not dose escalate to twice daily dosing with nevirapine. The once daily dosing regimen should not be continued beyond 28 days at which point an alternative regimen should be sought.
Description of Clinical Studies:

Lamivudine, Zidovudine, and Nevirapine: There have been no clinical trials conducted with Lamivudine, Zidovudine, and Nevirapine Tablets. See CLINICAL PHARMACOLOGY for information about pharmacokinetic comparability.

Lamivudine Plus Zidovudine: The NUCB3007 (CAESAR) study was conducted using lamivudine 150-mg Tablets (150 mg twice daily) and zidovudine 100-mg Capsules (2 x 100 mg 3 times daily). CAESAR was a multi-center, double-blind, placebo-controlled study comparing continued current therapy [zidovudine alone (62% of patients) or zidovudine with didanosine or zalcitabine (38% of patients)] to the addition of lamivudine or lamivudine plus an investigational non-nucleoside reverse transcriptase inhibitor, randomized 1:2:1. A total of 1,816 HIV-1-infected adults with 25 to 250 (median 122) CD4+ cells/mm³ at baseline were enrolled: median age was 36 years, 87% were male, 84% were nucleoside-experienced, and 16% were therapy-naive. The median duration on study was 12 months. Results are summarized in Table 7.

Table 7. Number of Patients (%) With At Least 1 HIV Disease-Progression Event or Death

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Current Therapy (n = 460)</th>
<th>Lamivudine plus Current Therapy (n = 896)</th>
<th>Lamivudine plus an NNRTI* plus Current Therapy (n = 460)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV progression or death</td>
<td>90 (19.6%)</td>
<td>86 (9.6%)</td>
<td>41 (8.9%)</td>
</tr>
<tr>
<td>Death</td>
<td>27 (5.9%)</td>
<td>23 (2.6%)</td>
<td>14 (3.0%)</td>
</tr>
</tbody>
</table>

* An investigational non-nucleoside reverse transcriptase inhibitor not approved in the United States.

Nevirapine: Trial BI 1090, was a placebo-controlled, double-blind, randomized trial in 2249 HIV-1-infected patients with <200 CD4+ cells/mm³ at screening. Initiated in 1995, BI 1090 compared treatment with nevirapine + lamivudine + background therapy versus lamivudine + background therapy in NNRTI naïve patients. Treatment doses were nevirapine 200 mg daily for two weeks followed by 200 mg twice daily or placebo, and lamivudine 150 mg twice daily. Other antiretroviral agents were given at approved doses. Initial background therapy (in addition to lamivudine) was one NRTI in 1309 patients (58%), two or more NRTIs in 771 (34%), and PIs and NRTIs in 169 (8%). The patients (median age 36.5 years, 70% Caucasian, 79% male) had advanced HIV infection, with a median baseline CD4+ cell count of 96 cells/mm³ and a baseline HIV RNA of 4.58 log₁₀ copies/mL (38,291 copies/mL). Prior to entering the trial, 45% had previously experienced an AIDS-defining clinical event. Eighty-nine percent had antiretroviral treatment prior to entering the trial. BI 1090 was originally designed as a clinical endpoint
study. Prior to unblinding the trial, the primary endpoint was changed to proportion of patients with HIV RNA <50 copies/mL and not previously failed at 48 weeks. Treatment response and outcomes are shown in Table 8.

**Table 8. BI 1090 Outcomes through 48 weeks**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Nevirapine (N=1121) %</th>
<th>Placebo (N=1128) %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Responders at 48 weeks: HIV RNA &lt;50 copies/mL</td>
<td>18.0</td>
<td>1.6</td>
</tr>
<tr>
<td>Treatment Failure</td>
<td>82.0</td>
<td>98.4</td>
</tr>
<tr>
<td>Never suppressed viral load</td>
<td>44.6</td>
<td>66.4</td>
</tr>
<tr>
<td>Virologic failure after response</td>
<td>7.2</td>
<td>4.3</td>
</tr>
<tr>
<td>CDC category C event or death</td>
<td>9.6</td>
<td>11.2</td>
</tr>
<tr>
<td>Added antiretroviral therapy while &lt;50 copies/mL</td>
<td>5.0</td>
<td>0.9</td>
</tr>
<tr>
<td>Discontinued trial therapy due to AE</td>
<td>7.0</td>
<td>5.9</td>
</tr>
<tr>
<td>Discontinued trial &lt;48 weeks¹</td>
<td>8.5</td>
<td>9.8</td>
</tr>
</tbody>
</table>

¹ including change to open-label NVP  
² includes withdrawal of consent, lost to follow-up, non-compliance with protocol, other administrative reasons

The change from baseline in CD4+ cell count through one year of therapy was significantly greater for the nevirapine group compared to the placebo group for the overall study population (64 cells/mm³ vs. 22 cells/mm³, respectively), as well as for patients who entered the trial as treatment naive or having received only ZDV (85 cells/mm³ vs. 25 cells/mm³, respectively).

At two years into the study, 16% of subjects on nevirapine had experienced class C CDC events as compared to 21% of subjects on the control arm.

**Trial BI 1046** (INCAS) was a double-blind, placebo-controlled, randomized, three arm trial with 151 HIV-1 infected patients with CD4+ cell counts of 200-600 cells/mm³ at baseline. BI 1046 compared treatment with nevirapine + zidovudine + didanosine to nevirapine + zidovudine and zidovudine + didanosine. Treatment doses were nevirapine at 200 mg daily for two weeks followed by 200 mg twice daily or placebo, zidovudine at 200 mg three times daily, and didanosine at 125 or 200 mg twice daily (depending on body weight). The patients had mean baseline HIV RNA of 4.41 log₁₀ copies/mL (25,704 copies/mL) and mean baseline CD4+ cell count of 376 cells/mm³. The primary endpoint was the proportion of patients with HIV-RNA < 400 copies/mL and not previously failed at 48 weeks. The virologic responder rates at 48 weeks were 45% for patients treated with nevirapine...
+didanosine, 19% for patients treated with zidovudine+didanosine, and 0% for patients treated with nevirapine +zidovudine.

CD4+ cell counts in the nevirapine + zidovudine+didanosine group increased above baseline by a mean of 139 cells/mm$^3$ at one year, significantly greater than the increase of 87 cells/mm$^3$ in the zidovudine+didanosine. The nevirapine + zidovudine group mean decreased by 6 cells/mm$^3$ below baseline.

**CONTRAINDICATIONS**

- Lamivudine, Nevirapine, and Zidovudine Tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g. anaphylaxis) to any of the components of the formulation.

- Lamivudine, Nevirapine, and Zidovudine Tablets are contraindicated in patients with moderate or severe (Child Pugh Class B or C, respectively) hepatic impairment. [See WARNINGS and CLINICAL PHARMACOLOGY: Special Populations].

**WARNINGS**

Lamivudine, Nevirapine, and Zidovudine Tablets should not be administered concomitantly with formulations containing any of these three drugs.

The complete prescribing information for all agents being considered for use with Lamivudine, Nevirapine, and Zidovudine Tablets should be consulted before combination therapy with Lamivudine, Nevirapine, and Zidovudine Tablets is initiated.

**Lamivudine:**

*Post-treatment Exacerbations of Hepatitis*

In clinical trials in non-HIV-1-infected Patients treated with lamivudine for chronic HBV, clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of lamivudine. These exacerbations have been detected primarily by serum ALT elevations in addition to re-emergence of Hepatitis B Viral DNA (HBV DNA). Although most events appear to have been self-limited, fatalities have been reported in some cases. Similar events have been reported from post marketing experience after changes from lamivudine-containing HIV – 1 treatment regimens to non-lamivudine-containing regimens in patients infected with both HIV-1 and HBV. The causal relationship to discontinuation of lamivudine treatment is unknown. Patients should be closely monitored with both clinical and laboratory follows up for at least several months after stopping treatment. There is insufficient evidence to determine whether re-initiation of lamivudine alters the course of post treatment exacerbations of hepatitis.
Lamivudine and Zidovudine:

**Lactic Acidosis/Hepatomegaly with Steatosis**

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including lamivudine, zidovudine, and other antiretrovirals. A majority of these cases have been in women. Obesity and prolonged exposure to antiretroviral nucleoside analogues may be risk factors. Particular caution should be exercised when administering lamivudine and/or zidovudine to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with lamivudine- and/or zidovudine-containing products should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).

**Use With Interferon- and Ribavirin-Based Regimens**

In vitro studies have shown ribavirin can reduce the phosphorylation of pyrimidine nucleoside analogues such as lamivudine and zidovudine. Although no evidence of a pharmacokinetic or pharmacodynamic interaction (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with lamivudine or zidovudine in HIV-1/HCV co-infected patients (see CLINICAL PHARMACOLOGY: Drug Interactions), hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin. Patients receiving interferon alfa with or without ribavirin and Lamivudine, Nevirapine, and Zidovudine Tablets should be closely monitored for treatment-associated toxicities, especially hepatic decompensation, neutropenia, and anemia. Discontinuation of Lamivudine, Nevirapine, and Zidovudine Tablets should be considered as medically appropriate. Dose reduction or discontinuation of interferon alfa, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Childs Pugh >6). (see the complete prescribing information for interferon and ribavirin).

Exacerbation of anemia has been reported in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Co-administration of ribavirin and zidovudine is not advised.

Nevirapine:

**General:** The most serious adverse reactions associated with nevirapine are hepatitis/hepatic failure, Stevens–Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions. Hepatitis/hepatic failure may be associated with signs of hypersensitivity which can include severe rash or rash
accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, eosinophilia, granulocytopenia, lymphadenopathy, or renal dysfunction.

The first 18 weeks of therapy with nevirapine are a critical period during which intensive clinical and laboratory monitoring of patients is required to detect potentially life threatening hepatic events and skin reactions. The optimal frequency of monitoring during this time period has not been established. Some experts recommend clinical and laboratory monitoring more often than once per month, and in particular, would include monitoring of liver enzyme tests at baseline, prior to dose escalation and at two weeks post-dose escalation. After the initial 18-week period, frequent clinical and laboratory monitoring should continue throughout nevirapine treatment. In addition, the 14-day lead-in period with nevirapine 200 mg daily dosing has been demonstrated to reduce the frequency or rash (see DOSAGE AND ADMINISTRATION).

**Hepatotoxicity and Hepatic Impairment**

Severe, life-threatening, and in some cases fatal hepatotoxicity, including fulminant and cholestatic hepatitis, hepatic necrosis and hepatic failure, have been reported in patients treated with nevirapine. In controlled clinical trials, symptomatic hepatic events regardless of severity occurred in 4% (range 0% to 11.0%) of patients who received nevirapine and 1.2% of patients in control groups. The risk of symptomatic hepatic events regardless of severity was greatest in the first 6 weeks of therapy. The risk continued to be greater in the nevirapine groups compared to controls through 18 weeks of treatment. However, hepatic events may occur at any time during treatment. In some cases, patients presented with nonspecific, prodromal signs or symptoms of fatigue, malaise, anorexia, nausea, jaundice, liver tenderness or hepatomegaly, with or without initially abnormal serum transaminase levels. Rash was observed in approximately half of the patients with symptomatic hepatic adverse events. Fever and flu-like symptoms accompanied some of these hepatic events. Some events, particularly those with rash and other symptoms, have progressed to hepatic failure with transaminase elevation, with or without hyperbilirubinemia, hepatic encephalopathy, prolonged partial thromboplastin time, or eosinophilia. Rhabdomyolysis has been observed in some patients experiencing skin and/or liver reactions associated with nevirapine use. Patients with signs or symptoms of hepatitis must be advised to discontinue nevirapine-containing products and immediately seek medical evaluation, which should include liver enzyme tests.

Transaminases should be checked immediately if a patient experiences signs or symptoms suggestive of hepatitis and/or hypersensitivity reaction. Transaminases should also be checked immediately for all patients who develop a rash in the first 18 weeks of treatment. Physicians and patients should be vigilant for the appearance of signs or symptoms of hepatitis, such as fatigue,
malaise, anorexia, nausea, jaundice, bilirubinuria, acholic stools, liver tenderness or hepatomegaly. The diagnosis of hepatotoxicity should be considered in this setting, even if transaminases are initially normal or alternative diagnoses are possible (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).

If clinical hepatitis or transaminase elevations combined with rash or other systemic symptoms occur, Lamivudine, Nevirapine, and Zidovudine Tablets should be permanently discontinued. Do not restart Lamivudine, Nevirapine, and Zidovudine Tablets after recovery. In some cases, hepatic injury progresses despite discontinuation of treatment.

The patients at greatest risk of hepatic events, including potentially fatal events, are women with high CD4+ cell counts. In general, during the first 6 weeks of treatment, women have a three fold higher risk than men for symptomatic, often rash-associated, hepatic events (5.8% versus 2.2%), and patients with higher CD4+ cell counts at initiation of nevirapine therapy are at higher risk for symptomatic hepatic events with nevirapine. In a retrospective review, women with CD4+ cell counts >250 cells/mm³ had a 12 fold higher risk of symptomatic hepatic adverse events compared to women with CD4+ cell counts <250 cells/mm³ (11.0% versus 0.9%). An increased risk was observed in men with CD4+ cell counts >400 cells/mm³ (6.3% versus 1.2% for men with CD4+ cell counts <400 cells/mm³). However, all patients, regardless of gender, CD4+ cell count, or antiretroviral treatment history, should be monitored for hepatotoxicity since symptomatic hepatic adverse events have been reported at all CD4+ cell counts. Co-infection with hepatitis B or C and/or increased transaminase elevations at the start of therapy with nevirapine are associated with a greater risk of later symptomatic events (6 weeks or more after starting nevirapine) and asymptomatic increases in AST or ALT.

In addition, serious hepatotoxicity (including liver failure requiring transplantation in one instance) has been reported in HIV-uninfected individuals receiving multiple doses of nevirapine in the setting of post-exposure prophylaxis, an unapproved use.

Increased nevirapine trough concentrations have been observed in some patients with hepatic fibrosis or cirrhosis. Therefore, patients with either hepatic fibrosis or cirrhosis should be monitored carefully for evidence of drug induced toxicity. Nevirapine should not be administered to patients with moderate or severe (Child Pugh Class B or C, respectively) hepatic impairment (See CONTRAINDICATIONS).

Because increased nevirapine levels and nevirapine accumulation may be observed in patients with serious liver disease, nevirapine should not be administered to patients with severe hepatic impairment. (see CLINICAL PHARMACOLOGY, Pharmacokinetics in Special Populations: Hepatic Impairment; PRECAUTIONS: General).
**Skin Reactions**

Severe and life-threatening skin reactions, including fatal cases, have been reported, occurring most frequently during the first 6 weeks of therapy with nevirapine. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction including hepatic failure. Rhabdomyolysis has been observed in some patients experiencing skin and/or liver reactions associated with nevirapine use. In controlled clinical trials, Grade 3 and 4 rashes were reported during the first 6 weeks in 1.5% of nevirapine recipients compared to 0.1% of placebo subjects.

Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, and/or hepatitis, eosinophilia, granulocytopenia, lymphadenopathy, and renal dysfunction) must permanently discontinue nevirapine-containing products and seek medical evaluation immediately [*see precautions*]. Do not restart nevirapine-containing products following severe skin rash, skin rash combined with increased transaminases or other symptoms, or hypersensitivity reaction.

If patients present with a suspected nevirapine-associated rash, liver function tests should be performed. Patients with rash-associated AST or ALT elevations should be permanently discontinued from nevirapine-containing products.

Therapy with nevirapine must be initiated with a 14-day lead-in period of once daily dosing of 200 mg/day (150mg/m²/day in pediatric patients), which has been shown to reduce the frequency of rash. Nevirapine should be discontinued if a patient experiences severe rash or any rash accompanied by constitutional findings. A patient experiencing a mild to moderate rash without constitutional symptoms during the 14-day lead-in period of 200 mg/day (150mg/m²/day in pediatric patients) should not have their nevirapine dose increased until the rash has resolved. The total duration of the once daily lead-in dosing period should not exceed 28 days at which point an alternative regimen should be sought [*see Dosage and Administration*]. Patients should be monitored closely if isolated rash of any severity occurs. Delay in stopping nevirapine-containing treatment after the onset of rash may result in a more serious reaction.

Women appear to be at higher risk than men of developing rash with nevirapine. In a clinical trial, concomitant prednisone use (40 mg/day for the first 14 days of nevirapine administration) was associated
with an increase in incidence and severity of rash during the first 6 weeks of nevirapine therapy. Therefore, use of prednisone to prevent nevirapine-associated rash is not recommended.

**Resistance**

Nevirapine must not be used as a single agent to treat HIV-1 infection or added on as a sole agent to a failing regimen. Resistant virus emerges rapidly when nevirapine is administered as monotherapy. The choice of new antiretroviral agents to be used in combination with nevirapine should take into consideration the potential for cross resistance. When discontinuing an antiretroviral regimen containing nevirapine, the long half-life of nevirapine should be taken into account; if antiretrovirals with shorter half-lives than nevirapine are stopped concurrently, low plasma concentrations of nevirapine alone may persist for a week or longer and virus resistance may subsequently develop (see **CLINICAL PHARMACOLOGY**).

**St. John's Wort:** Concomitant use of St. John's wort (*Hypericum perforatum*) or St. John's wort containing products and nevirapine is not recommended. Co-administration of St. John’s wort with non-nucleoside reverse transcriptase inhibitors (NNRTIs), including nevirapine, is expected to substantially decrease NNRTI concentrations and may result in sub-optimal levels of nevirapine and lead to loss of virologic response and possible resistance to nevirapine or to the class of NNRTIs.

**Zidovudine**

**Hematologic Toxicity/Bone Marrow Suppression:** Zidovudine, a component of Lamivudine, Nevirapine, and Zidovudine Tablets, has been associated with hematologic toxicity including neutropenia and anemia, particularly in patients with advanced HIV-1 disease. Lamivudine, Nevirapine, and Zidovudine Tablets should be used with caution in patients who have bone marrow compromise evidenced by granulocyte count less than 1,000 cells/mm³ or hemoglobin less than 9.5 g/dL (see ADVERSE REACTIONS). Frequent blood counts are strongly recommended in patients with advanced HIV-1 disease who are treated with Lamivudine, Nevirapine, and Zidovudine Tablets. Periodic blood counts are recommended for other HIV-infected patients. If anemia or neutropenia develops, dosage interruption may be needed.

**Myopathy:** Myopathy and myositis, with pathological changes similar to that produced by HIV-1 disease, have been associated with prolonged use of zidovudine, and therefore may occur with therapy with Lamivudine, Nevirapine, and Zidovudine Tablets.

**Important Differences Among Lamivudine-, Nevirapine-, Zidovudine-, and/or Emtricitabine-Containing Products:**

Lamivudine, Nevirapine, and Zidovudine Tablets contain a higher dose of the same active ingredient (lamivudine) than in EPIVIR-HBV tablets and oral solution. EPIVIR-HBV was developed for patients
with chronic hepatitis B. The formulation and dosage of lamivudine in EPIVIR-HBV are not appropriate for patients co-infected with HIV-1 and HBV. Lamivudine, Nevirapine, and Zidovudine Tablets should not be administered concomitantly with other lamivudine-, zidovudine- or nevirapine-containing products, including EPIVIR (lamivudine), EPIVIR-HBV (lamivudine), COMBIVIR (lamivudine and zidovudine), TRIZIVIR (abacavir sulfate, lamivudine, and zidovudine), EPZICOM (abacavir sulfate and lamivudine), RETROVIR (zidovudine), VIRAMUNE (nevirapine) or emtricitabine-containing products, including ATRIPLA (efavirenz, emtricitabine, and tenofovir), EMTRIVA (emtricitabine), or TRUVADA (emtricitabine and tenofovir).

PRECAUTIONS

Lamivudine

Patients With HIV-1 and Hepatitis B Virus Co-infection: Safety and efficacy of lamivudine have not been established for treatment of chronic hepatitis B in patients dually infected with HIV-1 and HBV. In non-HIV-1-infected patients treated with lamivudine for chronic hepatitis B, emergence of lamivudine-resistant HBV has been detected and has been associated with diminished treatment response. Emergence of hepatitis B virus variants associated with resistance to lamivudine has also been reported in HIV-1-infected patients who have received lamivudine-containing antiretroviral regimens in the presence of concurrent infection with hepatitis B virus. Post treatment exacerbations of hepatitis have also been reported. (see WARNINGS).

Lamivudine, Nevirapine, and Zidovudine

Patients With Impaired Renal Function: Patients with creatinine clearance <50 mL/min or patients on hemodialysis should not receive Lamivudine, Nevirapine, and Zidovudine Tablets.

Patients With Impaired Hepatic Function: Lamivudine, Nevirapine, and Zidovudine Tablets are not recommended for patients with impaired hepatic function.

Immune reconstitution syndrome: Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including Lamivudine, Nevirapine and Zidovudine. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.

Fat Distribution: Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid
appearance,” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

Nevirapine

**General:** The most serious adverse reactions associated with nevirapine are hepatitis/hepatic failure, Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions. Hepatitis/hepatic failure may be isolated or associated with signs of hypersensitivity which may include severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, eosinophilia, granulocytopenia, lymphadenopathy, or renal dysfunction (see WARNINGS).

Nevirapine is extensively metabolized by the liver and nevirapine metabolites are extensively eliminated by the kidney. Nevirapine metabolites may accumulate in patients receiving dialysis; however, the clinical significance of this accumulation is not known (see CLINICAL PHARMACOLOGY: Pharmacokinetics in Special Populations: Renal Impairment; DOSAGE AND ADMINISTRATION: Dosage Adjustment).

The duration of clinical benefit from antiretroviral therapy may be limited. Patients receiving nevirapine or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV-1 infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with associated HIV-1 diseases.

When administering nevirapine as part of an antiretroviral regimen, the complete product information for each therapeutic component should be consulted before initiation of treatment.

**Information for Patients**

The Medication Guide provides written information for the patient, and should be dispensed with each new prescription and refill.

**Lamivudine, Nevirapine, and Zidovudine**

Lamivudine, Nevirapine, and Zidovudine Tablets are for oral ingestion only. Patient should be informed that Lamivudine, Nevirapine, and Zidovudine Tablets are not a cure for HIV-1 infection and patients may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. Patients should be advised that the use of Lamivudine, Nevirapine, and Zidovudine Tablets has not been shown to reduce the risk of transmission of HIV-1 to others through sexual contact or blood contamination. Patients should be advised of the importance of taking Lamivudine, Nevirapine and Zidovudine tablets exactly as it is prescribed. Patients should not alter the
dose without consulting their doctor. If a dose is missed, patients should take the next dose as soon as possible. However, if a dose is skipped, the patient should not double the next dose. Patients should be advised to report to their doctor the use of any other medications.

Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time.

**Lamivudine:** Patients co-infected with HIV-1 and HBV should be informed that deterioration of liver disease has occurred in some cases when treatment with lamivudine was discontinued. Patients should be advised to discuss any changes in regimen with their physician.

Patients should be advised that Lamivudine, Nevirapine, and Zidovudine Tablets contain a higher dose of the same active ingredient (lamivudine) as EPIVIR-HBV tablets. If a decision is made to include lamivudine in the HIV-1 treatment regimen of a patient dually infected with HIV-1 and HBV, the dosage of lamivudine in Lamivudine, Nevirapine, and Zidovudine Tablets (not EPIVIR-HBV) should be used.

**Nevirapine:** Patients should be informed of the possibility of severe liver disease or skin reactions associated with nevirapine that may result in death. Patients developing signs or symptoms of liver disease or severe skin reactions should be instructed to discontinue nevirapine and seek medical attention immediately, including performance of laboratory monitoring. Symptoms of liver disease include fatigue, malaise, anorexia, nausea, jaundice, acholic stools, liver tenderness or hepatomegaly. Symptoms of severe skin or hypersensitivity reactions include rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema and/or hepatitis.

Intensive clinical and laboratory monitoring, including liver enzymes tests, is essential during the first 18 weeks of therapy with nevirapine to detect potentially life-threatening hepatotoxicity and skin reactions. However, liver disease can occur after this period, therefore monitoring should continue at frequent intervals throughout nevirapine treatment. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of hepatic events and skin reactions. Patients with signs and symptoms of hepatitis should discontinue nevirapine and seek medical evaluation immediately. If nevirapine is discontinued due to hepatotoxicity, do not restart it. Patients, particularly women, with increased CD4+ cell count at initiation of nevirapine therapy (>250 cells/mm³ in women and >400 cells/mm³ in men) are at substantially higher risk for development of symptomatic hepatic events, often associated with rash. Patients should be advised that co-infection with hepatitis B or C and/or increased transaminase elevations at the start of therapy with nevirapine are associated with a greater risk of later
symptomatic events (6 weeks or more after starting nevirapine) and asymptomatic increases in AST or ALT (see WARNINGS; Hepatotoxicity and Hepatic Impairment).

The majority of rashes associated with nevirapine occur within the first 6 weeks of initiation of therapy. Patients should be instructed that if any rash occurs during the two-week lead-in period, the nevirapine dose should not be escalated until the rash resolves. Any patient experiencing a rash should have their liver function evaluated immediately. Patients with severe rash or hypersensitivity reactions should discontinue nevirapine immediately and consult a physician. Nevirapine should not be restarted following severe skin rash or hypersensitivity reaction. Women tend to be at higher risk for development of nevirapine associated rash.

**Contraceptives**

Oral contraceptives and other hormonal methods of birth control should not be used as the sole method of contraception in women taking nevirapine, since nevirapine may lower the plasma levels of these medications. Additionally, when oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored [see Drug Interactions].

**Methadone**

Based on the known metabolism of methadone, nevirapine may decrease plasma concentrations of methadone by increasing its hepatic metabolism. Narcotic withdrawal syndrome has been reported in patients treated with nevirapine and methadone concomitantly. Methadone-maintained patients beginning nevirapine therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly [see Drug Interactions].

Nevirapine may interact with some drugs, therefore, patients should be advised to report to their doctor the use of other prescription, non-prescription medication or herbal products, particularly St. John’s wort.

**Zidovudine**: Patients should be informed that the important toxicities associated with zidovudine are neutropenia and/or anemia. They should be told of the extreme importance of having their blood counts followed closely while on therapy, especially for patients with advanced HIV-1 disease.
**Drug Interactions**

**Lamivudine:** When administered concomitantly, no change in dose of trimethoprim (TMP) 160 mg/sulfamethoxazole (SMX) 800 mg or lamivudine is recommended. There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat PCP.

**Nevirapine:**

Nevirapine is principally metabolized by the liver via the cytochrome P450 isoenzymes, 3A and 2B6. Nevirapine is known to be an inducer of these enzymes. As a result, drugs that are metabolized by these enzyme systems may have lower than expected plasma levels when co-administered with nevirapine.

The specific pharmacokinetic changes that occur with co-administration of nevirapine and other drugs are listed in CLINICAL PHARMACOLOGY, Table 2. Clinical comments about possible dosage modifications based on established drug interactions are listed in Table 9. The data in Tables 2 and 9 are based on the results of drug interaction studies conducted in HIV-1 seropositive subjects unless otherwise indicated.

In addition to established drug interactions, there may be potential pharmacokinetic interactions between nevirapine and other drug classes that are metabolized by the cytochrome P450 system. These potential drug interactions are also listed in Table 9. Although specific drug interaction studies in HIV-1 seropositive subjects have not been conducted for some classes of drugs listed in Table 9, additional clinical monitoring may be warranted when co-administering these drugs.

The *in vitro* interaction between nevirapine and the antithrombotic agent warfarin is complex. As a result, when giving these drugs concomitantly, plasma warfarin levels may change with the potential for increases in coagulation time. When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.
Table 9. Established and Potential Drug Interactions: Use With Caution, Alteration in Dose or Regimen May Be Needed due to Drug Interaction Established Drug Interactions: Table 2 for Magnitude of Interaction.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Effect on Concentration of Nevirapine or Concomitant Drug</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atazanavir/Ritonavir</td>
<td>↓ Atazanavir ↑ Nevirapine</td>
<td>Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure.</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>↓ Clarithromycin ↑ 14-OH clarithromycin</td>
<td>Clarithromycin exposure was significantly decreased by nevirapine; however, 14-OH metabolite concentrations were increased. Because clarithromycin’s active metabolite has reduced activity against <em>Mycobacterium avium-intracellulare complex</em>, overall activity against this pathogen may be altered. Alternatives to clarithromycin, such as azithromycin, should be considered.</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>↓ Efavirenz</td>
<td>There has been no determination of appropriate doses for the safe and effective use of this combination.</td>
</tr>
<tr>
<td>Ethinyl estradiol and Norethindrone</td>
<td>↓ Ethinyl estradiol ↓ Norethindrone</td>
<td>Oral contraceptives and other hormonal methods of birth control should not be used as the sole method of contraception in women taking nevirapine, since nevirapine may lower the plasma levels of these medications. An alternative or additional method of contraception is recommended.</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>↑ Nevirapine</td>
<td>Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events.</td>
</tr>
<tr>
<td>Fosamprenavir/Ritonavir</td>
<td>↓ Amprenavir ↑ Nevirapine</td>
<td>Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended.</td>
</tr>
<tr>
<td>Indinavir</td>
<td>↓ Indinavir</td>
<td>Appropriate doses for this combination are not established, but an increase in the dosage of indinavir may be required.</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>↓ Ketoconazole</td>
<td>Nevirapine and ketoconazole should not be administered concomitantly because decreases in ketoconazole plasma concentrations may reduce the efficacy of the drug.</td>
</tr>
<tr>
<td>Lopinavir/Ritonavir</td>
<td>↓ Lopinavir</td>
<td>Lopinavir/ritonavir 400/100 mg tablets can be used twice-daily in combination with nevirapine with no dose adjustment in antiretroviral-naïve patients. A dose increase of Lopinavir/ritonavir tablets to 600/150 mg (3 tablets) twice daily may be considered when used in combination with nevirapine in treatment experienced patients where decreased susceptibility to lopinavir is clinically suspected (by treatment history or laboratory evidence). A dose increase of lopinavir/ritonavir oral solution to 533/133 mg twice daily with food is recommended in combination with nevirapine.</td>
</tr>
</tbody>
</table>
In children 6 months to 12 years of age, consideration should be given to increasing the dose of lopinavir/ritonavir to 13/3.25 mg/kg for those 7 to < 15 kg; 11/2.75 mg/kg for those 15 to 45 kg; and up to a maximum dose of 533/133 mg for those > 45 kg twice daily when used in combination with nevirapine, particularly for patients in whom reduced susceptibility to lopinavir/ritonavir is suspected. Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly. The appropriate dose for nelfinavir in combination with nevirapine, with respect to safety and efficacy, has not been established.

Rifabutin

Rifampin

Saquinavir/ritonavir

Potential Drug Interactions:

Drug Class

Examples of Drugs

Antiarrhythmics

Amiodarone, disopyramide, lidocaine

Plasma concentrations may be decreased

Anticonvulsants

Carbamazepine, clonazepam, ethosuximide

Plasma concentrations may be decreased

Antifungals

Itraconazole

Plasma concentrations of some azole antifungals may be decreased. Nevirapine and itraconazole should not be administered concomitantly due to a potential decrease in itraconazole plasma concentrations.

Calcium channel blockers

Diltiazem, nifedipine, verapamil

Plasma concentrations may be decreased

Cancer chemotherapy

Cyclophosphamide

Plasma concentrations may be decreased

Ergot alkaloids

Ergotamine

Plasma concentrations may be decreased

Immunosuppressant

Cyclosporin, tacrolimus, sirolimus

Plasma concentrations may be decreased

Motility agents

Cisapride

Plasma concentrations may be decreased.

Opiate agonists

Fentanyl

Plasma concentrations may be decreased

Antithrombotics

Warfarin

Plasma concentrations may be increased. Potential effect on anticoagulation. Monitoring of anticoagulation levels is recommended.
Based on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.

Table 10: Potential Drug Interactions: Use With Caution, Dose Adjustment of Co-administered Drug May Be Needed due to Possible Decrease in Clinical Effect

<table>
<thead>
<tr>
<th>Examples of Drugs in Which Plasma Concentrations May Be Decreased By Co-administration With Nevirapine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drug Class</strong></td>
</tr>
<tr>
<td>Antiarrhythmics</td>
</tr>
<tr>
<td>Anticonvulsants</td>
</tr>
<tr>
<td>Antifungals</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
</tr>
<tr>
<td>Cancer chemotherapy</td>
</tr>
<tr>
<td>Ergot alkaloids</td>
</tr>
<tr>
<td>Immunosuppressants</td>
</tr>
<tr>
<td>Motility agents</td>
</tr>
<tr>
<td>Opiate agonists</td>
</tr>
</tbody>
</table>

Examples of Drugs in Which Plasma Concentrations May Be Increased By Co-administration With Nevirapine

| Warfarin                                             | Potential effect on anticoagulation. Monitoring of anticoagulation levels is recommended. |

Zidovudine: Coadministration of ganciclovir, interferon alfa, and other bone marrow suppressive or cytotoxic agents may increase the hematologic toxicity of zidovudine. Concomitant use of zidovudine with stavudine should be avoided since an antagonistic relationship with zidovudine has been demonstrated in vitro. In addition, concomitant use of zidovudine with doxorubicin or ribavirin should be avoided because an antagonistic relationship with zidovudine has been demonstrated in vitro.

See CLINICAL PHARMACOLOGY for additional drug interactions.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Carcinogenicity:

Lamivudine: Long-term carcinogenicity studies with lamivudine in mice and rats showed no evidence of carcinogenic potential at exposures up to 10 times (mice) and 58 times (rats) those observed in humans at the recommended therapeutic dose for HIV-1 infection.

Nevirapine: Long-term carcinogenicity studies in mice and rats were carried out with nevirapine. Mice were dosed with 0, 50, 375 or 750 mg/kg/day for two years. Hepatocellular adenomas and carcinomas were increased at all doses in males and at the two high doses in females. In studies in which rats were
administered nevirapine at doses of 0, 3.5, 17.5 or 35 mg/kg/day for two years, an increase in hepatocellular adenomas was seen in males at all doses and in females at the high dose. The systemic exposure (based on AUCs) at all doses in the two animal studies were lower than that measured in humans at the 200 mg BID dose. The mechanism of the carcinogenic potential is unknown.

**Zidovudine:** Zidovudine was administered orally at 3 dosage levels to separate groups of mice and rats (60 females and 60 males in each group). Initial single daily doses were 30, 60, and 120 mg/kg/day in mice and 80, 220, and 600 mg/kg/day in rats. The doses in mice were reduced to 20, 0, and 40 mg/kg/day after day 90 because of treatment-related anemia, whereas in rats only the high dose was reduced to 450 mg/kg/day on day 91 and then to 300 mg/kg/day on day 279.

In mice, 7 late-appearing (after 19 months) vaginal neoplasms (5 nonmetastasizing squamous cell carcinomas, 1 squamous cell papilloma, and 1 squamous polyp) occurred in animals given the highest dose. One late-appearing squamous cell papilloma occurred in the vagina of a middle-dose animal. No vaginal tumors were found at the lowest dose.

In rats, 2 late-appearing (after 20 months), nonmetastasizing vaginal squamous cell carcinomas occurred in animals given the highest dose. No vaginal tumors occurred at the low or middle dose in rats. No other drug-related tumors were observed in either sex of either species.

At doses that produced tumors in mice and rats, the estimated drug exposure (as measured by AUC) was approximately 3 times (mouse) and 24 times (rat) the estimated human exposure at the recommended therapeutic dose of 100 mg every 4 hours.

It is not known how predictive the results of rodent carcinogenicity studies may be for humans.

**Mutagenicity:**

**Lamivudine:** Lamivudine was mutagenic in an L5178Y/TK+/- mouse lymphoma assay and clastogenic in a cytogenetic assay using cultured human lymphocytes. Lamivudine was negative in a microbial mutagenicity assay, in an in vitro cell transformation assay, in a rat micronucleus test, in a rat bone marrow cytogenetic assay, and in an assay for unscheduled DNA synthesis in rat liver.

**Nevirapine:** In genetic toxicology assays, nevirapine showed no evidence of mutagenic or clastogenic activity in a battery of *in vitro* and *in vivo* studies. These included microbial assays for gene mutation (Ames: Salmonella strains and *E. coli*), mammalian cell gene mutation assay (CHO/HGPRT), cytogenetic assays using a Chinese hamster ovary cell line and a mouse bone marrow micronucleus assay following
oral administration. Given the lack of genotoxic activity of Nevirapine, the relevance to humans of hepatocellular neoplasms in Nevirapine treated mice and rats are not known.

**Zidovudine:** Zidovudine was mutagenic in an L5178Y/TK+/- mouse lymphoma assay, positive in an in vitro cell transformation assay, clastogenic in a cytogenetic assay using cultured human lymphocytes, and positive in mouse and rat micronucleus tests after repeated doses. It was negative in a cytogenetic study in rats given a single dose.

**Impairment of Fertility:**

**Lamivudine:** In a study of reproductive performance, lamivudine, administered to male and female rats at doses up to 130 times the usual adult dose based on body surface area considerations, revealed no evidence of impaired fertility (judged by conception rates) and no effect on the survival, growth, and development to weaning of the offspring.

**Nevirapine:** In reproductive toxicology studies, evidence of impaired fertility was seen in female rats at doses providing systemic exposure, based on AUC, approximately equivalent to that provided with the recommended clinical dose of nevirapine.

**Zidovudine:** Zidovudine, administered to male and female rats at doses up to 7 times the usual adult dose based on body surface area considerations, had no effect on fertility judged by conception rates.

**Pregnancy: Pregnancy Category C.**

Lamivudine and zidovudine are classified under category C. Nevirapine is classified under category B.

**Lamivudine, Nevirapine, and Zidovudine**

There are no adequate and well-controlled studies in pregnant women. Lamivudine, Nevirapine, and Zidovudine Tablets should be used during pregnancy only if the potential benefits outweigh the potential risk to the fetus.

**Lamivudine:** Reproduction studies have been performed in rats and rabbits at orally administered doses up to 4,000 mg/kg/day and 1,000 mg/kg/day, respectively, producing plasma levels up to approximately 35 times that for the adult HIV dose. No evidence of teratogenicity due to lamivudine was observed. Evidence of early embryolethality was seen in the rabbit at exposure levels similar to those observed in humans, but there was no indication of this effect in the rat at exposure levels up to 35 times those in humans. Studies in pregnant rats and rabbits showed that lamivudine is transferred to the fetus through the placenta.
**Zidovudine**: Oral teratology studies in rat and in rabbit at doses up to 500 mg/kg/day revealed no evidence of teratogenicity with zidovudine. Zidovudine treatment resulted in embryo/fetal toxicity as evidenced by an increase in the incidence of fetal resorptions in rats given 150 or 450 mg/kg/day and rabbits given 500 mg/kg/day. The doses used in the teratology studies resulted in peak zidovudine plasma concentrations (after one half of the daily dose) in rats 66 to 226 times, and in rabbits 12 to 87 times, mean steady-state peak human plasma concentrations (after one sixth of the daily dose) achieved with the recommended daily dose (100 mg every 4 hours). In an in vivo experiment with fertilized mouse oocytes, zidovudine exposure resulted in a dose-dependent reduction in blastocyst formation. In an additional teratology study in rats, a dose of 3,000 mg/kg/day (very near the oral median lethal dose in rats of 3,683 mg/kg) caused marked maternal toxicity and an increase in the incidence of fetal malformations. This dose resulted in peak zidovudine plasma concentrations 350 times peak human plasma concentrations (Estimated AUC in rats at this dose level was 300 times the daily exposure AUC in humans given 600 mg/day). No evidence of teratogenicity was seen in this experiment at doses of 600 mg/kg/day or less. Two rodent carcinogenicity studies were conducted [see Carcinogenesis, Mutagenesis, and Impairment of Fertility].

**Nevirapine**

No observable teratogenicity was detected in reproductive studies performed in pregnant rats and rabbits. The maternal and developmental no-observable-effect level dosages produced systemic exposures approximately equivalent to or approximately 50% higher in rats and rabbits, respectively, than those seen at the recommended daily human dose (based on AUC). In rats, decreased fetal body weights were observed due to administration of a maternally toxic dose (exposures approximately 50% higher than that seen at the recommended human clinical dose).

There are no adequate and well-controlled studies of Nevirapine in pregnant women. The Antiretroviral Pregnancy Registry, which has been surveying pregnancy outcomes since January 1989, has not found an increased risk of birth defects following first trimester exposures to Nevirapine. The prevalence of birth defects after any trimester exposure to Nevirapine is comparable to the prevalence observed in the general population.

Severe hepatic events, including fatalities, have been reported in pregnant women receiving chronic nevirapine therapy as part of combination treatment of HIV-1 infection. Regardless of pregnancy status women with CD4+ cell counts >250 cells/mm\(^3\) should not initiate nevirapine unless the benefit outweighs the risk. It is unclear if pregnancy augments the risk observed in non-pregnant women (see WARNINGS).
Nursing Mothers
The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection.

Because of both the potential for HIV-1 transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed if they are receiving Lamivudine, Nevirapine, and Zidovudine Tablets.

Lamivudine and Zidovudine: Lactation studies performed with lamivudine and zidovudine show that both drugs are excreted in human breast milk. Samples of breast milk obtained from 20 mothers receiving lamivudine monotherapy (300 mg twice daily) or combination therapy (150 mg lamivudine twice daily and 300 mg zidovudine twice daily) had measurable concentrations of lamivudine. In another study, after administration of a single dose of 200 mg zidovudine to 13 HIV-1-infected women, the mean concentration of zidovudine was similar in human milk and serum.

Nevirapine: Nevirapine is excreted in breast milk.

Pediatric Use:

Lamivudine:
The safety and effectiveness of twice-daily lamivudine in combination with other antiretroviral agents have been established in pediatric patients 3 months of age and older (see Adverse Reactions, Clinical Pharmacology, Clinical Studies).

Nevirapine:
The safety, pharmacokinetic profile, and virologic and immunologic responses of nevirapine have been evaluated in HIV-infected pediatric patients age 3 months to 18 years [see Adverse Reactions and Clinical Studies]. The safety and pharmacokinetic profile of nevirapine has been evaluated in HIV-infected pediatric patients age 15 days to < 3 months [see Adverse Reactions and Clinical Studies].

The most frequently reported adverse events related to nevirapine in pediatric patients were similar to those observed in adults, with the exception of granulocytopenia, which was more commonly observed in children receiving both zidovudine and nevirapine [(see Adverse Reactions and Clinical Studies].

Zidovudine:
Zidovudine has been studied in HIV-1-infected pediatric patients ≥6 weeks of age who had HIV-1-related symptoms or who were asymptomatic with abnormal laboratory values indicating significant HIV-1-
related immunosuppression. Zidovudine has also been studied in neonates perinatally exposed to HIV-1 [see Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies].

**Geriatric Use:** Clinical studies of lamivudine, nevirapine, and zidovudine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Therefore, Lamivudine, Nevirapine, and Zidovudine Tablets are not recommended for patients with impaired renal function (i.e., creatinine clearance <50 mL/min; see PRECAUTIONS: Patients with Impaired Renal Function and DOSAGE AND ADMINISTRATION) or patients on hemodialysis.

**Patients With Impaired Renal Function:**
Because it is a fixed-dose combination, Lamivudine, Nevirapine and Zidovudine Tablets should not be prescribed for patients requiring dosage adjustment such as those with renal impairment.

**Hepatic Impairment**

**Nevirapine:**
Because increased nevirapine levels and nevirapine accumulation may be observed in patients with serious liver disease, do not administer nevirapine to patients with moderate or severe (Child Pugh Class B or C, respectively) hepatic impairment [see Contraindications, Warnings and Precautions, and Clinical Pharmacology].

**Zidovudine:**
Zidovudine is eliminated from the body primarily by renal excretion following metabolism in the liver (glucuronidation). Although the data are limited, zidovudine concentrations appear to be increased in patients with severely impaired hepatic function which may increase the risk of hematologic toxicity [see Dosage and Administration; Clinical Pharmacology].

**ADVERSE REACTIONS**
The adverse events reported with lamivudine, zidovudine, and nevirapine are presented below.

**Adults**

**Lamivudine Plus Zidovudine Administered As Separate Formulations:** In 4 randomized, controlled trials of lamivudine 300 mg per day plus zidovudine 600 mg per day, the following selected clinical and laboratory adverse events were observed [see Tables 11 and 12].
Table 11. Selected Clinical Adverse Events (≥5% Frequency) in 4 Controlled Clinical Trials With lamivudine 300 mg/day and zidovudine 600 mg/day

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Lamivudine plus Zidovudine (n = 251)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Body as a whole</strong></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>35%</td>
</tr>
<tr>
<td>Malaise &amp; fatigue</td>
<td>27%</td>
</tr>
<tr>
<td>Fever or chills</td>
<td>10%</td>
</tr>
<tr>
<td><strong>Digestive</strong></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>33%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>18%</td>
</tr>
<tr>
<td>Nausea &amp; vomiting</td>
<td>13%</td>
</tr>
<tr>
<td>Anorexia and/or decreased appetite</td>
<td>10%</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>9%</td>
</tr>
<tr>
<td>Abdominal cramps</td>
<td>6%</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>5%</td>
</tr>
<tr>
<td><strong>Nervous system</strong></td>
<td></td>
</tr>
<tr>
<td>Neuropathy</td>
<td>12%</td>
</tr>
<tr>
<td>Insomnia &amp; other sleep disorders</td>
<td>11%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>10%</td>
</tr>
<tr>
<td>Depressive disorders</td>
<td>9%</td>
</tr>
<tr>
<td><strong>Respiratory</strong></td>
<td></td>
</tr>
<tr>
<td>Nasal signs &amp; symptoms</td>
<td>20%</td>
</tr>
<tr>
<td>Cough</td>
<td>18%</td>
</tr>
<tr>
<td><strong>Skin</strong></td>
<td></td>
</tr>
<tr>
<td>Skin rashes</td>
<td>9%</td>
</tr>
<tr>
<td><strong>Musculoskeletal</strong></td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal pain</td>
<td>12%</td>
</tr>
<tr>
<td>Myalgia</td>
<td>8%</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5%</td>
</tr>
</tbody>
</table>

Pancreatitis was observed in 9 of the 2,613 adult patients (0.3%) who received lamivudine in controlled clinical trials.

Selected laboratory abnormalities observed during therapy are listed in Table 12.

Table 12. Frequencies of Selected Laboratory Abnormalities Among Adults in 4 Controlled Clinical Trials of lamivudine 300 mg/day plus zidovudine 600 mg/day

<table>
<thead>
<tr>
<th>Test (Abnormal Level)</th>
<th>Lamivudine plus Zidovudine % (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutropenia (ANC&lt;750/mm³)</td>
<td>7.2% (237)</td>
</tr>
<tr>
<td>Anemia (Hgb&lt;8.0 g/dL)</td>
<td>2.9% (241)</td>
</tr>
<tr>
<td>Thrombocytopenia (platelets&lt;50,000/mm³)</td>
<td>0.4% (240)</td>
</tr>
<tr>
<td>ALT (&gt;5.0 x ULN)</td>
<td>3.7% (241)</td>
</tr>
<tr>
<td>AST (&gt;5.0 x ULN)</td>
<td>1.7% (241)</td>
</tr>
<tr>
<td>Bilirubin (&gt;2.5 x ULN)</td>
<td>0.8% (241)</td>
</tr>
<tr>
<td>Amylase (&gt;2.0 x ULN)</td>
<td>4.2% (72)</td>
</tr>
</tbody>
</table>

ULN = Upper limit of normal.
ANC = Absolute neutrophil count.
n = Number of patients assessed.
Frequencies of these laboratory abnormalities were higher in patients with mild laboratory abnormalities at baseline.

**Post-Marketing Surveillance:** In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of lamivudine, zidovudine, and/or lamivudine and zidovudine. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to lamivudine, zidovudine, and/or lamivudine/zidovudine.

**Body as a Whole:** Redistribution/accumulation of body fat [see Precautions: Fat Redistribution].

**Cardiovascular:** Cardiomyopathy.

**Endocrine and Metabolic:** Gynecomastia, hyperglycemia.

**Gastrointestinal:** Oral mucosal pigmentation, stomatitis.

**General:** Vasculitis, weakness.

**Hematologic and Lymphatic:** Anemia, (including pure red cell aplasia and severe anemias progressing on therapy), lymphadenopathy, splenomegaly.

**Hepatic and Pancreatic:** Lactic acidosis and hepatic steatosis, pancreatitis, posttreatment exacerbation of hepatitis B [see warnings].

**Hypersensitivity:** Sensitization reactions (including anaphylaxis), urticaria.

**Musculoskeletal:** Muscle weakness, CPK elevation, rhabdomyolysis.

**Nervous:** Paresthesia, peripheral neuropathy, seizures.

**Respiratory:** Abnormal breath sounds/wheezing.

**Skin:** Alopecia, erythema multiforme, Stevens-Johnson syndrome.

**Nevirapine:**

**Clinical Trials in Adults**

The most serious adverse events associated with nevirapine are hepatitis, hepatic failure, Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions. Hepatitis/hepatic failure may be isolated or associated with signs of hypersensitivity which may include severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, eosinophilia, granulocytopenia, lymphadenopathy, or renal dysfunction (see WARNINGS).

**Hepatic Reaction**

In controlled clinical trials, symptomatic hepatic events regardless of severity occurred in 4.0% (range 0% to 11.0%) of patients who received nevirapine and 1.2% of patients in control groups. Female gender and
higher CD4+ cell counts (>250 cells/mm$^3$ in women and >400 cells/mm$^3$ in men) place patients at increased risk of these events (see WARNINGS).

Asymptomatic transaminase elevations (AST or ALT > 5X ULN) were observed in 5.8% (range 0% to 9.2%) of patients who received nevirapine and 5.5% of patients in control groups. Co-infection with hepatitis B or C and/or increased transaminase elevations at the start of therapy with nevirapine are associated with a greater risk of later symptomatic events (6 weeks or more after starting nevirapine) and asymptomatic increases in AST or ALT.

Liver enzyme abnormalities (AST, ALT, GGT) were observed more frequently in patients receiving nevirapine than in controls (see Table 14).

**Skin Reactions:** The most common clinical toxicity of nevirapine is rash, which can be severe or life-threatening [see Warnings]. Rash occurs most frequently within the first 6 weeks of therapy. Rashes are usually mild to moderate, maculopapular erythematous cutaneous eruptions, with or without pruritus, located on the trunk, face and extremities. In controlled clinical trials (Trials 1037, 1038, 1046, and 1090), Grade 1 and 2 rashes were reported in 13.3% of patients receiving nevirapine compared to 5.8% receiving placebo during the first 6 weeks of therapy. Grade 3 and 4 rashes were reported in 1.5% of nevirapine recipients compared to 0.1% of subjects receiving placebo. Women tend to be at higher risk for development of nevirapine associated rash [see Warnings]. Because clinical trials are conducted under widely varying conditions, adverse events rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Treatment related, adverse experiences of moderate or severe intensity observed in >2% of patients receiving nevirapine in placebo-controlled trials are shown in Table 13.
### Table 13: Percentage of Patients with Moderate or Severe Drug Related Events in Adult Placebo Controlled Trials

<table>
<thead>
<tr>
<th></th>
<th>Trial 1090(^1)</th>
<th>Trials 1037, 1038, 1046(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nevirapine (n=1121)</td>
<td>Placebo (n=1128)</td>
</tr>
<tr>
<td>Median exposure (weeks)</td>
<td>58</td>
<td>52</td>
</tr>
<tr>
<td>Any adverse event</td>
<td>14.5 %</td>
<td>11.1 %</td>
</tr>
<tr>
<td>Rash</td>
<td>5.1</td>
<td>1.8</td>
</tr>
<tr>
<td>Nausea</td>
<td>0.5</td>
<td>1.1</td>
</tr>
<tr>
<td>Granulocytopenia</td>
<td>1.8</td>
<td>2.8</td>
</tr>
<tr>
<td>Headache</td>
<td>0.7</td>
<td>0.4</td>
</tr>
<tr>
<td>Fatigue</td>
<td>0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>0.2</td>
<td>0.8</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>0.1</td>
<td>0.4</td>
</tr>
<tr>
<td>Myalgia</td>
<td>0.2</td>
<td>0</td>
</tr>
</tbody>
</table>

1 Background therapy included 3TC for all patients and combinations of NRTIs and PIs. Patients had CD4+ cell counts <200 cells/mm³.

2 Background therapy included zidovudine and zidovudine plus didanosine; nevirapine monotherapy was administered in some patients. Patients had CD4+ cell count >200 cells/mm³.

**Laboratory Abnormalities:** Liver enzyme test abnormalities (AST, ALT) were observed more frequently in patients receiving nevirapine than in controls (Table 14). Asymptomatic elevations in GGT occur frequently but are not a contraindication to continue nevirapine therapy in the absence of elevations in other liver enzyme tests. Other laboratory abnormalities (bilirubin, anemia, neutropenia, and thrombocytopenia) were observed with similar frequencies in clinical trials comparing nevirapine and control regimens [see Table 14].
Table 14: Percentage of Adult Patients with Laboratory Abnormalities

<table>
<thead>
<tr>
<th>Laboratory Abnormality</th>
<th>Trial 1090(^1)</th>
<th>Placebo (^1)</th>
<th>Trials 1037, 1038, 1046(^2)</th>
<th>Placebo (^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nevirapine ((n=1121))</td>
<td>Nevirapine ((n=1128))</td>
<td>Nevirapine ((n=253))</td>
<td>Nevirapine ((n=203))</td>
</tr>
<tr>
<td><strong>Blood Chemistry</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SGPT (ALT) &gt;250 U/L</td>
<td>5.3 %</td>
<td>4.4 %</td>
<td>14.0 %</td>
<td>4.0 %</td>
</tr>
<tr>
<td>SGOT (AST) &gt;250 U/L</td>
<td>3.7</td>
<td>2.5</td>
<td>7.6</td>
<td>1.5</td>
</tr>
<tr>
<td>Bilirubin &gt;2.5 mg/dL</td>
<td>1.7</td>
<td>2.2</td>
<td>1.7</td>
<td>1.5</td>
</tr>
<tr>
<td><strong>Hematology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin &lt;8.0 g/dL</td>
<td>3.2</td>
<td>4.1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Platelets &lt;50,000/mm(^3)</td>
<td>1.3</td>
<td>1.0</td>
<td>0.4</td>
<td>1.5</td>
</tr>
<tr>
<td>Neutrophils &lt;750/mm(^3)</td>
<td>13.3</td>
<td>13.5</td>
<td>3.6</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Background therapy included 3TC for all patients and combinations of NRTIs and PIs. Patients had CD4+ cell counts <200 cells/mm\(^3\). Background therapy included zidovudine and didanosine; nevirapine monotherapy was administered in some patients. Patients had CD4+ cell count ≥200 cells/mm\(^3\).

**Post-Marketing Surveillance:** In addition to the adverse events identified during clinical trials, the following adverse reactions have been identified during post-approval use of nevirapine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Body as a Whole:** fever, somnolence, drug withdrawal [see PRECAUTIONS: Drug Interactions], redistribution/accumulation of body fat [see Precautions: Fat Redistributions]

**Gastrointestinal:** vomiting

**Liver and Biliary:** jaundice, fulminant and cholestatic hepatitis, hepatic necrosis, hepatic failure

**Hematology:** anemia, eosinophilia, neutropenia

**Musculoskeletal:** arthralgia, rhabdomyolysis associated with skin and/or liver reactions

**Neurologic:** paraesthesia

**Skin and Appendages:** allergic reactions including anaphylaxis, angioedema, bullous eruptions, ulcerative stomatitis and urticaria have all been reported. In addition, hypersensitivity syndrome and hypersensitivity reactions with rash associated with constitutional findings such as fever, blistering, oral lesions, conjunctivitis, facial edema, muscle or joint aches, general malaise, fatigue or significant hepatic abnormalities [see Warnings] plus one or more of the following: hepatitis, eosinophilia, granulocytopenia, lymphadenopathy and/or renal dysfunction have been reported with the use of nevirapine.
In post-marketing surveillance anemia has been more commonly observed in children although development of anemia due to concomitant medication use cannot be ruled out.

OVERDOSAGE

Lamivudine, Nevirapine, and Zidovudine: There is no known antidote for Lamivudine, Nevirapine, and Zidovudine Tablets.

Lamivudine: One case of an adult ingesting 6 grams of lamivudine was reported; there were no clinical signs or symptoms noted and hematologic tests remained normal. Two cases of pediatric overdose were reported in ACTG300. One case involved a single dose of 7 mg/kg of lamivudine; the second case involved use of 5 mg/kg of lamivudine twice daily for 30 days. There were no clinical signs or symptoms noted in either case. Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event.

Nevirapine

There is no known antidote for nevirapine overdose. Cases of nevirapine overdose at doses ranging from 800 to 1800 mg per day for up to 15 days have been reported. Patients have experienced events including edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonary infiltrates, rash, vertigo, vomiting and weight decrease. All events subsided following discontinuation of nevirapine.

Zidovudine: Acute overdoses of zidovudine have been reported in pediatric patients and adults. These involved exposures up to 50 grams. The only consistent findings were nausea and vomiting. Other reported occurrences included headache, dizziness, drowsiness, lethargy, confusion, and 1 report of a grand mal seizure. Hematologic changes were transient. All patients recovered. Hemodialysis and peritoneal dialysis appear to have a negligible effect on the removal of zidovudine, while elimination of its primary metabolite, GZDV, is enhanced.

DOSAGE AND ADMINISTRATION

Pediatric Patients (≥ 5 Kg body weight and > 3 months of age)

Lamivudine, nevirapine and zidovudine tablets for oral suspension (containing 30 mg of lamivudine, 50 mg of nevirapine and 60 mg of zidovudine) cannot be administered for the first 2-week lead-in period of once-daily nevirapine administration (this lead-in period must be used because it has been found to lessen the frequency of rash).
The recommended oral dose of lamivudine, nevirapine and zidovudine tablets for oral suspension in HIV-l-infected pediatric patients 3 months or more of age and weighing ≥ 5 kg, after the lead-in period of nevirapine, is provided in Table 15.

Prescribers should calculate the appropriate dose of Lamivudine, nevirapine and zidovudine for each child based on body weight (kg) and should not exceed the recommended adult dose.

The lamivudine, nevirapine and zidovudine tablets for oral suspension are scored tablets.

Half or whole tablets can be swallowed with water. For children unable to swallow the tablet(s), a mixture (suspension) with water can be made with the following procedure:

Preparation of Suspension:

1. Place the tablet(s) in container and add two teaspoonfuls (10 mL) of water per tablet.

2. Swirl the container until tablet(s) breaks up into pieces small enough for the child to swallow, a spoon can be used to crush the pieces, if needed.

3. Drink the mixture within 1 hour.

4. Rinse the container with additional small amount of water and drink the contents to assure that the entire dosage is taken.

This product may be administered with or without food.

Table 15: Recommended Pediatric Dosage

<table>
<thead>
<tr>
<th>Weight Range (Body weight in kg)</th>
<th>Dosing</th>
<th>Lamivudine (AM dose in mg/ PM dose in mg)</th>
<th>Nevirapine (AM dose in mg/ PM dose in mg)</th>
<th>Zidovudine (AM dose in mg/ PM dose in mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 - &lt;7</td>
<td>1 tablet BID</td>
<td>30/30</td>
<td>50/50</td>
<td>60/60</td>
</tr>
<tr>
<td>7 - &lt;11</td>
<td>1.5 tablets BID</td>
<td>45/45</td>
<td>75/75</td>
<td>90/90</td>
</tr>
<tr>
<td>11 - &lt;14</td>
<td>2 tablets BID</td>
<td>60/60</td>
<td>100/100</td>
<td>120/120</td>
</tr>
<tr>
<td>14 - &lt;18</td>
<td>2.5 tablets BID</td>
<td>75/75</td>
<td>125/125</td>
<td>150/150</td>
</tr>
<tr>
<td>18 - &lt;22</td>
<td>3 tablets BID</td>
<td>90/90</td>
<td>150/150</td>
<td>180/180</td>
</tr>
<tr>
<td>22 - &lt;25</td>
<td>3.5 tablets BID</td>
<td>105/105</td>
<td>175/175</td>
<td>210/210</td>
</tr>
<tr>
<td>&gt;25</td>
<td>Adult dose BID</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adults and Adolescents ≥16 years of age
The recommended oral dose of lamivudine, nevirapine and zidovudine in HIV-1-infected adults and adolescents >16 years of age is one tablet (containing 150 mg of lamivudine, 200 mg of nevirapine and 300 mg of zidovudine) twice daily after the lead-in period of nevirapine.

Monitoring of Patients
Intensive clinical and laboratory monitoring, including liver enzyme tests, is essential at baseline and during the first 18 weeks of treatment with nevirapine. The optimal frequency of monitoring during this period has not been established. Some experts recommend clinical and laboratory monitoring more often than once per month, and in particular, would include monitoring of liver enzyme tests at baseline, prior to dose escalation, and at two weeks post dose escalation. After the initial 18 week period, frequent clinical and laboratory monitoring should continue throughout nevirapine treatment [see Warnings and Precautions]. In some cases, hepatic injury has progressed despite discontinuation of treatment.

Dosage Adjustment

Because it is a fixed-dose combination, lamivudine, nevirapine and zidovudine should not be prescribed for patients requiring dosage adjustment such as those with renal impairment, or patients with hepatic impairment.

Nevirapine:

Patients with Rash
Nevirapine should be discontinued if a patient experiences severe rash or any rash accompanied by constitutional findings [see Boxed Warning, Warnings and Precautions, and Patient Counseling Information]. A patient experiencing mild to moderate rash without constitutional symptoms during the 14-day lead-in period of once daily nevirapine dosing with 200 mg/day in adults (150 mg/m2/day in pediatric patients) should not have their nevirapine dose increased until the rash has resolved [see Warnings and Precautions) and Patient Counseling Information]. The total duration of the once daily lead-in dosing period should not exceed 28 days at which point an alternative regimen should be sought.

Patients with Hepatic Events
If a clinical (symptomatic) hepatic event occurs, nevirapine should be permanently discontinued. Do not restart nevirapine after recovery [see Warnings and Precautions].
Patients with Dose Interruption
Patients who interrupt nevirapine dosing for more than 7 days should restart the recommended dosing, using one 200 mg tablet daily (150mg/m²/day in pediatric patients) for the first 14 days (lead-in) followed by one 200 mg tablet twice daily (150 mg/m² twice daily for pediatric patients).

Zidovudine:
Patients with Severe Anemia and/or Neutropenia
Significant anemia (hemoglobin <7.5 g/dL or reduction >25% of baseline) and/or significant neutropenia (granulocyte count <750 cells/mm³ or reduction >50% from baseline) may require a dose interruption until evidence of marrow recovery is observed [see Warnings and Precautions]. In patients who develop significant anemia, dose interruption does not necessarily eliminate the need for transfusion. If marrow recovery occurs following dose interruption, resumption in dose may be appropriate using adjunctive measures such as epoetin alfa at recommended doses, depending on hematologic indices such as serum erythropoietin level and patient tolerance.

HOW SUPPLIED
Lamivudine, Nevirapine and Zidovudine Tablets for Oral Suspension: 30 mg/50 mg/60 mg; Yellow colored, mottled, round shaped, beveled edge tablets debossed with ‘M09’ and breakline on one side and plain on the other.

Bottle of 60 tablets NDC 65015-114-17

Recommended Storage:
Store in tightly closed bottles at 25°C (77°F) excursions permitted to 15° to 30°C (59° to 86°F) (see USP Controlled Room Temperature).

COMBIVIR®, EPIVIR®, EPIVIR-HBV®, EPZICOM®, RETROVIR®, and TRIZIVIR® are registered are trademarks of GlaxoSmithKline. EMTRIVA® and TRUVADA® are trademarks of Gilead Sciences, Inc. ATRIPLA® is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. VIRAMUNE® is a trademark of Boehringer Ingelheim Pharmaceuticals Inc.
ATTENTION PHARMACISTS: Detach “Medication Guide” and dispense with the product.

MEDICATION GUIDE

Lamivudine, Nevirapine, and Zidovudine Tablets For Oral Solution, 30 mg/50 mg/60 mg

Generic name: Lamivudine (lah MIH vue deen), nevirapine (na VAIR a peen), and zidovudine (zye DOE vue deen) tablets

Read this Medication Guide before you start taking Lamivudine, Nevirapine, and Zidovudine Tablets and each time you get a refill because there may be new information. This information does not take the place of talking with your doctor. You and your doctor should discuss taking Lamivudine, Nevirapine, and Zidovudine Tablets when you start taking your medicine and at regular checkups. You should stay under a doctor's care while taking Lamivudine, Nevirapine, and Zidovudine Tablets. You should consult with your doctor before making any changes to your medications, except in any of the special circumstances described below regarding rash or liver problems.

What is the most important information I should know about taking Lamivudine, Nevirapine, and Zidovudine Tablets?

Patients taking nevirapine (one component of Lamivudine, Nevirapine, and Zidovudine Tablets) may develop severe liver disease or skin reactions that can cause death. The risk of these reactions is greatest during the first 18 weeks of treatment, but these reactions also can occur later.

Take Lamivudine, Nevirapine, and Zidovudine Tablets exactly as instructed. Do not take more than the doctor told you to. Check the label carefully for how much to take and how often to take each medicine.

Your doctor will recommend that you take Lamivudine, Nevirapine, and Zidovudine Tablets twice a day only if you have tolerated a two week “lead-in” period in which you received pills containing nevirapine once daily (along with pills containing lamivudine and zidovudine taken twice daily).

Patients taking Lamivudine, Nevirapine, and Zidovudine Tablets may develop:
Liver Reactions

Any patient can experience liver problems while taking nevirapine (one component of Lamivudine, Nevirapine, and Zidovudine Tablets). However, women and patients who have higher CD4 counts when they begin nevirapine treatment have a greater chance of developing liver damage. Women with CD4 counts higher than 250 cells/mm³ are at the greatest risk of these events. If you are a woman with CD4 counts higher than 250 cells/mm³ or a man with CD4 count higher than 400 cells/mm³ you should not begin taking nevirapine unless you and your doctor have decided that the benefit of doing so outweighs the risk. Liver problems are often accompanied by a rash.

Patients starting nevirapine with abnormal liver function tests and patients with hepatitis B or C have a greater chance of developing further increases in liver function tests after starting nevirapine and throughout therapy.

In rare cases liver problems have led to liver failure and can lead to a liver transplant or death. Therefore, if you develop any of the following symptoms of liver problems, stop taking Lamivudine, Nevirapine, and Zidovudine Tablets and call your doctor right away:

- General ill feeling or “flu-like” symptoms,
- Tiredness,
- Nausea (feeling sick to your stomach),
- Lack of appetite
- Yellowing of your skin or whites of your eyes,
- Dark urine (tea colored),
- Pale stools (bowel movements),
- Pain, ache, or sensitivity to touch on your right side below your ribs.

Your doctor should check you and do blood tests often to check your liver function during the first 18 weeks of therapy. Checks for liver problems should continue regularly during treatment with Lamivudine, Nevirapine, and Zidovudine Tablets.

Worsening of hepatitis B virus (HBV) infection: Patients with HBV infection, who take Lamivudine, Nevirapine, and Zidovudine Tablets and then stop it, may get “flare-ups” of their hepatitis. “Flare-up” is when the disease suddenly returns in a worse way than before. If you have HBV infection, your doctor should closely monitor your liver function for several months after stopping Lamivudine, Nevirapine, and Zidovudine Tablets. You may need to take anti-HBV medications.
Use with interferon- and ribavirin-based regimens: Worsening of liver disease (sometimes resulting in death) has occurred in patients infected with both HIV and hepatitis C who are taking anti-HIV medicines and are also being treated for hepatitis C with interferon with or without ribavirin. If you are taking Lamivudine, Nevirapine, and Zidovudine Tablets as well as interferon with or without ribavirin and you experience side effects, be sure to tell your doctor.

Skin Reactions

Skin rash is the most common side effect of nevirapine (one component of Lamivudine, Nevirapine, and Zidovudine Tablets). Most rashes occur in the first 6 weeks of treatment. In a small number of patients, rash can be serious and result in death. Therefore, if you develop a rash with any of the following symptoms stop using nevirapine and call your doctor right away:

- General ill feeling or “flu-like” symptoms,
- Fever,
- Muscle or joint aches,
- Conjunctivitis (red or inflamed eyes, like “pink eye”),
- Blisters,
- Mouth sores,
- Swelling of your face,
- Tiredness,
- Any of the symptoms of liver problems discussed above

If your doctor tells you to stop treatment with nevirapine because you have experienced the serious liver or skin reactions described above, never take nevirapine again.

Lactic Acidosis

Lamivudine, Nevirapine, and Zidovudine Tablets can cause a condition called lactic acidosis, together with an enlarged liver. Symptoms of lactic acidosis may include:

- Feeling very weak and tired;
- Nausea, vomiting, or unusual or unexpected stomach discomfort;
- Shortness of breath;
- Weakness in arms and legs.
If you notice these symptoms or if your medical condition suddenly changes, stop taking Lamivudine, Nevirapine, and Zidovudine Tablets and call your doctor right away. Lactic acidosis is a medical emergency that must be treated in a hospital. This rare, but serious, side effect occurs more often in women (including pregnant women), overweight patients, and those who have been taking nucleoside medicines for a very long time. If you have liver disease you may also be more at risk of getting this condition. While you are being treated with Lamivudine, Nevirapine, and Zidovudine Tablets, your doctor will monitor you closely for any signs that you may be developing lactic acidosis.

**Pancreatitis**

Lamivudine Nevirapine, and Zidovudine Tablets can cause pancreatitis, a dangerous inflammation of the pancreas. It may cause death. Tell your doctor right away if you develop stomach pain, nausea, or vomiting. These can be signs of pancreatitis. Let your doctor know if you have ever had pancreatitis, regularly drink alcoholic beverages, or have gallstones. Pancreatitis occurs more often in patients with these conditions. It is also more likely in people with advanced HIV disease, but can occur at any disease stage.

**Hematologic Toxicity**

Zidovudine (one component of Lamivudine Nevirapine, and Zidovudine Tablets) has been associated with hematologic toxicity including neutropenia and/or anemia, particularly in patients with advanced HIV disease. Serious blood problems including low levels of red and/or white blood cells have occurred with the use of zidovudine. Contact your doctor immediately if you develop unusual fatigue, pale skin, sore throat, fever, or chills which may be signs of blood problems.

Prolonged use of lamivudine and zidovudine has been associated with symptomatic myopathy.

These are not all the side effects of lamivudine, zidovudine, and nevirapine. See the section "What are the possible side effects of Lamivudine Nevirapine, and Zidovudine Tablets?" for more information. Tell your doctor if you have any side effects from nevirapine.

**What are Lamivudine, Nevirapine, and Zidovudine Tablets?**

Lamivudine, Nevirapine, and Zidovudine Tablets are antivirals. These are medicines used to treat Human Immunodeficiency Virus (HIV), the virus that causes AIDS (Acquired Immune Deficiency Syndrome). They are in a category of HIV medicines called reverse transcriptase inhibitors. All three medicines work by lowering the amount of HIV in the blood ("viral load"). Lamivudine, Nevirapine, and Zidovudine Tablets can reduce viral load and increase the number of CD4 cells ("T cells"). CD4 cells are a type of
immune helper cell in the blood. Lamivudine, Nevirapine, and Zidovudine Tablets may not have these effects in every patient.

Lamivudine, Nevirapine, and Zidovudine Tablets do not cure HIV or AIDS. People taking Lamivudine, Nevirapine, and Zidovudine Tablets may still get infections common in people with HIV (opportunistic infections). Therefore, it is very important that you stay under the care of your doctor.

Lamivudine and zidovudine may also be used for purposes other than those listed in this medication guide.

**Who should not take Lamivudine, Nevirapine, and Zidovudine Tablets?**

- Do not take Lamivudine, Nevirapine, and Zidovudine Tablets if: You are allergic to lamivudine, nevirapine, and zidovudine or any of their inactive ingredients. Your doctor or pharmacist can tell you about the inactive ingredients.

- Do not restart Lamivudine, Nevirapine, and Zidovudine Tablets after you recover from side effects of these medications such as serious liver or skin reactions, blood problems, or lactic acidosis that happened when you took Lamivudine, Nevirapine, and Zidovudine Tablets or any of the individual active ingredients.

- Do not take Lamivudine, Nevirapine, and Zidovudine Tablets if you take certain medicines. (See “Can I take other medicines with Lamivudine, Nevirapine, and Zidovudine Tablets?” for a list of medicines)

- Do not take these medications if you are not infected with HIV.

**What should I tell my doctor before taking Lamivudine, Nevirapine, and Zidovudine Tablets?**

Before starting Lamivudine, Nevirapine, and Zidovudine Tablets, tell your doctor about all of your medical conditions, including if you:

- have problems with your liver or have had hepatitis

- have kidney disease or are undergoing dialysis

- have skin conditions, such as a rash

- are pregnant, planning to become pregnant, or are breast feeding

- have bone marrow suppression
**How should I take Lamivudine, Nevirapine, and Zidovudine Tablets?**

- Take the exact amount of lamivudine, nevirapine, and zidovudine your doctor prescribes. The dose of lamivudine, nevirapine, and zidovudine for children is based on their size. Children’s dosing of the Lamivudine, Nevirapine, and Zidovudine tablets starts after patients have taken 14 days of another formulation of lamivudine, nevirapine, and zidovudine. Check with your doctor to see what medication you should take during the first 14 days of nevirapine (“lead-in period”) before starting the Lamivudine, Nevirapine, and Zidovudine tablets.

Half or whole tablets can be swallowed with water. For children unable to swallow the tablet(s), a mixture (suspension) with water can be made with the following procedure:

**Preparation of Suspension:**

1. Place the tablet(s) in container and add two teaspoonfuls (10 mL) of water per tablet.

2. Swirl the container until tablet(s) breaks up into pieces small enough for the child to swallow, a spoon can be used to crush the pieces, if needed.

3. Drink the mixture within 1 hour.

4. Rinse the container with additional small amount of water and drink the contents to assure that the entire dosage is taken.

Lamivudine, nevirapine, and zidovudine may be taken with or without food.

- Do not miss a dose of lamivudine, nevirapine, and zidovudine, because this could make the virus harder to treat. If you forget to take lamivudine, nevirapine, and zidovudine, take the missed dose right away. If it is almost time for your next dose, do not take the missed dose. Instead, follow your regular dosing schedule by taking the next dose at its regular time.

- If you stop taking lamivudine, nevirapine, and zidovudine for more than 7 days, ask your doctor how much to take before you start taking it again. You may need to start with once-a-day dosing.

- If you suspect that you have taken too much lamivudine, nevirapine, and zidovudine, contact your local poison control center or emergency room right away.
Can I take other medicines with Lamivudine, Nevirapine, and Zidovudine Tablets?

Other medications may interact with these medications resulting in decreased effectiveness and/or side effects. Talk to your doctor and pharmacist before taking any other prescription or over-the-counter medicines, including vitamins, minerals, and herbal products during treatment.

- Do not take Nizoral (ketoconazole) or Rifadin/Rifamate/Rifater (rifampin) with nevirapine (one component of Lamivudine, Nevirapine, and Zidovudine Tablets)

- Tell your doctor if you take Biaxin (clarithromycin), Diflucan (fluconazole), methadone, or Mycobutin (rifabutin). Nevirapine (one component of Lamivudine, Nevirapine, and Zidovudine Tablets) may not be right for you, or you may need careful monitoring.

- Tell your doctor if you take ganciclovir, interferon alfa, ribavirin, and other bone marrow suppressive or cytotoxic agents. Zidovudine (one component of Lamivudine, Nevirapine, and Zidovudine Tablets) may not be right for you, or you may need careful monitoring.

- It is recommended that you not take products containing St. John’s wort, which can reduce the amount of nevirapine (one component of Lamivudine, Nevirapine, and Zidovudine Tablets) in your body.

- If you take birth control pills, you should not rely on them to prevent pregnancy. They may not work if you take nevirapine (one component of Lamivudine, Nevirapine, and Zidovudine Tablets). Talk with your doctor about other types of birth control that you can use.

What should I avoid while taking Lamivudine, Nevirapine, and Zidovudine Tablets?

Follow your doctor’s instructions with respect to high-risk activities such as unprotected sex and personal items that can have blood or body fluids on them, like toothbrushes, razor blades, and needles. Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood. These medications do not cure HIV or AIDS and you can still transmit the virus to other during therapy with these medications. The Centers for Disease Control and Prevention advises mothers with HIV not to breast feed so they will not pass HIV to the infant through their milk. Ask your doctor about the best way to feed your infant.

Avoid alcohol. Alcohol may increase the risk of damage to the pancreas and/or liver.

What are the possible side effects of Lamivudine, Nevirapine, and Zidovudine Tablets?

(Also see "What is the most important information I should know about Lamivudine, Nevirapine, and Zidovudine Tablets?" at the beginning of this Medication Guide.)

Lamivudine, Nevirapine, and Zidovudine Tablets can cause
• Serious blood problems including low levels of red and/or white blood cells have occurred with the use of zidovudine. Contact your doctor immediately if you develop unusual fatigue, pale skin, sore throat, fever, or chills which may be signs of blood problems.

• Lactic acidosis and liver problems, including fatal cases, have been reported with the use of reverse transcriptase inhibitors, such as lamivudine and zidovudine, alone or in combination. Contact your doctor immediately if you experience nausea, vomiting, or unusual or unexpected stomach discomfort; weakness and tiredness; shortness of breath; weakness in the arms and legs; yellowing of the skin or eyes; or pain in the upper stomach area. These may be early symptoms of lactic acidosis or liver problems.

• Changes in body fat: These changes have happened in patients taking antiretroviral medicines like lamivudine, nevirapine, and zidovudine. The changes may include increased amount of fat in the upper back and neck (“buffalo hump”), breast, and around the trunk. Loss of fat from the legs, arms, and face may also happen. The cause and long-term health effects of these conditions are not known at this time.

• Serious liver damage and skin reactions that can cause death. Any patient can experience such side effects, but some patients are more at risk than others. (See "What is the most important information I should know about Lamivudine, Nevirapine, and Zidovudine Tablets?" at the beginning of this Medication Guide.)

• Other common side effects of nevirapine (one component of Lamivudine, Nevirapine, and Zidovudine Tablets) include nausea, fatigue, fever, headache, vomiting, diarrhea, abdominal pain, and myalgias. This list of side effects is not complete. Ask your doctor or pharmacist for more information.

If you experience any of the following serious side effects, stop taking this combination of lamivudine nevirapine, and zidovudine and seek emergency medical attention or notify your doctor immediately:

• an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);

• muscle pain or weakness; or

• peripheral neuropathy (nerve damage), which may cause numbness, tingling, or pain
Other, less serious side effects may be more likely to occur.

- mild nausea, vomiting, diarrhea, or decreased appetite;
- a headache;
- dizziness;
- depression/anxiety
- myalgia
- fever
- insomnia

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

**How do I store Lamivudine, Nevirapine, and Zidovudine Tablets?**

Store the tablets at room temperature, between 59° to 86°F (15° to 30°C). Keep nevirapine and all medicines out of the reach of children.

**General information about Lamivudine, Nevirapine, and Zidovudine Tablets**

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Lamivudine, Nevirapine, and Zidovudine Tablets for a condition for which they were not prescribed. Do not give Lamivudine, Nevirapine, and Zidovudine Tablets to other people, even if they have the same condition you have. They may harm them.

This Medication Guide summarizes the most important information about Lamivudine, Nevirapine, and Zidovudine Tablets. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about these medications that is written for health professionals.

For any further information contact

**Manufactured By:**

Matrix Laboratories Ltd,
Secunderabad, India.

**Revision: July 2010**